CURRICULUM VITAE - MD Anderson Cancer Center GI_Cancer... · Web viewV Int. Symposium on Microsomes and Drug Oxidations, Tokyo, Japan: "Central control of sexual differentiation of

Revised February 6, 2009 Jan-Åke Gustafsson, M.D., Ph.D.

CURRICULUM VITAE

Name: Jan-Åke Gustafsson, M.D., Ph.D.

Date of Birth: August 4, 1943

Education: Ph.D., Dept of Chemistry, Karolinska Institutet, 1968M.D., Karolinska Institutet, 1971

Career/Academic Appointments:

1964 Bachelor of Medicine, Karolinska Institutet, Stockholm1971 Associate Professor in Chemistry, Karolinska Institutet1976 Professor of Chemistry, Karolinska Institutet1978 Professor of Chemistry, University of Gothenburg1979 Professor of Medical Nutrition and Chairman of the Dept of Medical

Nutrition, Huddinge University Hospital, Karolinska Institutet2006-present Professor of Medical Nutrition and Chairman of the Dept of Biosciences and

Nutrition, Karolinska Institutet

Administrative Positions:

1985 Director of the Center for Biotechnology, Huddinge University Hospital, Karolinska Institutet

1987 Founder of KaroBio AB (a campus-situated biotechnology company sponsored by pension and governmental funds with about 80 employees).

1979 – 1991 Project leader of the Swedish EPA research program on Air Pollution in Urban Areas

2004-present Coordinator for the EU funded CASCADE Network of Excellence

Professional Honors & Recognition

A) International/National/Regional 2008 Foreign Member Finnish Scientific Society 2008 EMD Serono President’s Distinguished Lecture. Annual Meeting of the Society for

Gynecological Investigation, San Diego.2008 International Member American Philosophical Society2005 Descartes Research Prize for excellence in scientific collaborative research2005 2nd Ernst Knobil Memorial Lecture, San Diego, USA2004 Medal from Biomedicum Helsinki2004 Bristol-Meyers Squibb/Mead Johnson Award for Nutrition Research2003 FEBS Lectureship Datta Award2003 McDowell Lecture in Physiology, King’s College, London, U.K.2002 Commandeur dans l’Ordre des Palmes Académiques2002 Foreign Honorary Member of the US National Academy of Sciences2002 Chairman of the Nobel Assembly of the Karolinska Institutet2002 Fred Conrad Koch Award (Endocrine Soceity USA)2001 The AF Group Prize for the creation of Novum Research Park2001 Lorenzini Gold Medal, Lorenzini Foundation2001 Vice chairman of the Nobel Assembly of the Karolinska Institutet

1


2000 One of ISI Top 258 Researchers in Biology & Biochemistry2000 Garvan International Fellow2000 Burroughs Wellcome Fund Lecture2000 Foreign Honorary Member of the American Academy of Arts and Sciences2000 European Medal, British Society for Endocrinology2000 Curt Nicolin’s Prize for Achievements for the Development of South Stockholm1999 Medal of the IngaBritt and Arne Lundberg’s Research Foundation1999 Fogarty Scholar NIH1998 Adjunct Member of the Nobel Committee of the Karolinska Institutet1998 The Söderberg Prize in Medicine1998 Member of the Swedish Academy of Engineering Sciences1997 Member of the Swedish Academy of Sciences1994 Gregory Pincus Medal and Award, Worcester Foundation1992 Keith Harris Lecture, Australian Endocrine Society, Adelaide1992 The Anders Jahre Prize, Oslo1992 Medal from Collège de France, Paris1990 Honorary Member of the American Society for Biochemistry and Molecular Biology1986 Honorary Member of the Japanese Biochemical Society1986 Member of the Nobel Assembly of the Karolinska Institutet1983 The Fernström Prize of the Karolinska Institutet1982 The Svedberg Prize in Chemistry, Stockholm

B) University

2008 Honorary Professor at the Beijing Normal University2008 Honorary doctorate in Medicinal and Pharmaceutical Chemistry at the University of

Milan2007 Honorary Professor at the University of Chongquin, China2004 Guest Professor at the University of Science and Technology of China, Hefei2003 J.G. Moore Visiting Professor, UCLA, USA2003 Marius Tausk Visiting Professor at the Leiden University Medical Centre (LUMC)2002 Burroughs Wellcome Fund Visiting Professor in the Basic Medical Sciences at the

University of Texas Medical Branch School of Medicine2000 Center for Bioenvironmental Research Distinguished Visiting Professor, Tulane

University, New Orleans1995 Sterling Visiting Professor, University of Pennsylvania, Philadelphia1991 Consultant to The Rockefeller University Hospital1987 Adjunct Full Professor at the Department of Cell Biology, Baylor College of

Medicine, Houston, Texas

Has participated in several international reviewing panels, e.g.:

1995 Chairman of a board evaluating the Center for Biotechnology, University of Oslo.1994 Member of a board evaluating the Center for Biotechnology, Helsinki.1991 As chairman of a board evaluating the Norwegian Biotechnology Program.

2


Peer Review Groups/Grant Study Sections:

2007 Member of the LTA (LAM Treatment Alliance) SAB (Scientific Advisory Board, Boston.2007 Member of the IRB Barcelona External Advisory Board.2007 Member of the selection committee for The King Faisal International Prize in Science.2005-2007 Member of the International Academic Advisory Committee (IAAC), Hefei,

Peoples’s Republic of China.1995-Member of the International Advisory Board of the WHO Center in Oulu.

Journal Service:

Member, currently and/or previously, of the editorial board or similar position in Steroids, The Journal of Steroid Biochemistry and Molecular Biology, Molecular Endocrinology, Breast Cancer Research and Treatment, The Prostate, Anticancer Research, Japanese Journal of Cancer Research, Journal of Molecular Medicine, Molecular Pharmacology, Cell Metabolism, Experimental Biology and Medicine and the International Journal of Oncology.

Board Certification:

Elected Councillor/Board Member of the Swedish Medical Research Council during the 1990íes (for 6 years).Member of the Research Board of the Swedish Cancer Society during the 1980íes and 1990íes (for 6 years).Member of the Research Board of the Swedish Council for Planning and Coordination of Research during the 1980íes and 1990íes (for 6 years).Has been member of the Faculty Board of the Karolinska Institutet and regularly carries out various assignments for the President’s Office of the Karolinska Institutet.Awards Committee Member, Endocrine Society, USA 2002-06.Elected Member of Council (Board) of Endocrine Society, USA, 2007 –

Organisation of International conferences:

1983 Nobel symposium “Steroid hormone receptors: Structure and function”.

1988 2nd CBT Symposium “The steroid/thyroid hormone receptor family and gene regulation”.

1993 5th CBT Symposium “Intracellular hormone receptors and ligand-dependent transcriptional regulation”.

1995 7th CBT Symposium “Nuclear orphan receptors: Novel regulators in physiology and pathology”.

1995 EMBO Workshop; Structure and Function of Steroid and Nuclear Receptors, Alghero, Sardinia, Italy.

1997 9th CBT (Centre for Biotechnology) Symposium “Steroid and orphan nuclear receptors”, Huddinge, Sweden.

3


1999 Nobel symposium “Estrogens and women’s health – benefit or threat?”, Karlskoga, Sweden.

1999 EMBO Workshop; Steroids and Nuclear receptors, Villefranche, France.

2000 FEBS Advanced Study Institute, International Summer School on “New Dimensions in the Regulation of Gene Expression, Island of Spetses, Greece.

2000 10th CBT symposium “Nuclear receptors in health and disease”, Huddinge, Sweden.

2001 EMBO Workshop on Nuclear Receptor Structure and Function, Erice, Italy.

2002 “Nuclear Receptors 2002”, A joint International Symposium arranged by CBT, Karolinska Institutet, in collaboration with the Summer University of Southern Stockholm, Huddinge, Sweden.

2003 EMBO Conference, Biology of Nuclear Receptors, Villefranche-sur-Mer, France.

2003 Nobel Conference No 40: “Transcriptional control of lipid homeostasis”, Huddinge, Sweden.

2003 FEBS Advanced Study Institute, International Summer School on “From Transcription to Physiology: Regulation of Gene Expression and Protein Function in an Integrated Context”, Island of Spetses, Greece.

2004 “Nuclear Receptors 2004” An International Symposium arranged by CBT, Karolinska Institutet, Huddinge, Sweden.

2006 “Nuclear Receptors 2006” An International Symposium arranged by CBT, Karolinska Institutet, Huddinge, Sweden.

2007 Spetses Summer School on “Nuclear Receptor Signaling: From Molecular Mechanisms to Integrative Physiology”, Island of Spetses, Greece.

2008 Nobel Conference No 52 on “Recent advances in understanding estrogen signaling: From molecular insights to clinical implications”, Sånga-Säby, Stockholm, Sweden.

Patents, Softwares, Databases

Estrogen receptor -based hypertension treatment and assay.Patent No: GB 2374412

Estrogen receptors and their ligands for treating obesity and lowering lipoprotein levelsPatent No: US 2002151732

Cloning, characterization and pharmaceutical use of a mammalian nuclear receptor coactivator RAP250.Patent No: US 2002151477

Estrogen receptor beta (ER) agonists for use in cancer treatment.Patent No: GB 2361642

4


Method of estrogen receptor isoform detection via immunostaining and correlation with breast cancer.Patent No: GB 2361769

Cancer treatment and prognosis involving HES-1 protein.Patent No: WO 2001062792

Estrogen receptor agonists and antagonists for the treatment of growth or bone mineral density disorders.Patent No: WO 2000076529

Osteoporosis treatment with an estrogen receptor antagonists.Patent No: WO 2000061230

Estrogen receptor ER ligands for Vasculoprotectors.Patent No: WO 2000001716

Differential activation of estrogen receptors ERand ER at ap1 sites.Patent No: WO 9911760

Molecular cloning, cDNA sequences, and therapeutic uses of mammalian estrogen receptor.Patent No: WO 9709348

OR-1 orphan receptors belonging to the nuclear receptor family.Patent No: WO 605300

Other Activities:

Has participated in the supervision of 96 Ph.D. students to the presentation of their thesis.Has supervised 129 postdocs/visiting scientists.Has 1319 peer-reviewed publications. Can be sent upon request.Has so far been cited 61 912 times.

H-index: 108

Grant History:

A) Current Grants

Agency: Swedish Research CouncilI.D.# 701192301Title: “The oxysterol receptors LXRα and LXRβ in pathophysiology and molecular

mechanisms of metabolic, autoimmune and neurodegenerative disorders” P.I.: Jan-Åke Gustafsson, M.D., Ph.D., ProfessorPercent effort: 15%Direct costs per year: SEK 1,700,000/ $240,452Total costs for project period: SEK 5,100,000/ $721,358Project period: 01/01/2008 – 12/31/2010

Agency: Swedish Cancer SocietyI.D.# 07 0090

5


Title: “Estrogen receptor beta and estrogen related forms of cancer”P.I.: Jan-Åke Gustafsson, M.D., Ph.D., ProfessorPercent effort: 20%Direct costs per year: SEK 2,000,000/ $283,006Total costs for project period: SEK 6,000,000/ $849,017Project period: 01/01/2007 – 12/31/2009

Agency: EUI.D.# FOOD-CT-2004-506319Title: CASCADE “Chemicals as contaminants in the food chain: An NOE for

research, risk assessment and education”P.I.: Jan-Åke Gustafsson, M.D., Ph.D., ProfessorPercent effort: 15%Direct costs per year: EUR 195,810:80/ $265,030Total costs for project period: EUR 979,054/ $1,325,150 (our part)Project Period: 02/01/2004 – 01/31/2009

Agency: EUI.D.# LSHM-CT-2005-518245Title: EWA “Estrogens and women ageing”P.I.: Adriana Maggi, Ph.D., ProfessorRole on Project: PartnerPercent Effort: 5%Direct costs per year: EUR 70,000 / $94,745Total costs for the project period: EUR 210,000/ $284,235 (our part)Project Period: 01/01/2006 – 12/31/2008

Agency: EUI.D.# LSHM-CT-2005-018652Title: CRESCENDO “Consortium for Research into Nuclear Receptors in Development and Aging”P.I.: Barbara Demeneix, Ph.D., D.Sc., ProfessorRole on Project: PartnerPercent Effort: 5%Direct costs per year: EUR 99,240/ $181,804Total costs for the project period: EUR 496,200/ $909,020 (our part)Project Period: 03/01/2006 – 02/28/2011

Agency: EUI.D.# FOOD-CT-2005-513991Title: PIONEER “Puberty onset – influence on nutritional, environmental and

endogenous regulators”P.I.: Sari Mäkelä, M.D., Ph.D., ProfessorRole on Project: PartnerPercent Effort: 5%Direct costs per year: EUR 54,400/ $73,630Total costs for the project period: EUR 163,200/ $220,890 (our part)Project Period: 03/01/2005 – 02/28/2008

Agency: KaroBio ABI.D.# Cooperation grant

6


Title: “Orphan Receptors”P.I.: Jan-Åke Gustafsson, M.D., Ph.D., ProfessorPercent effort: 10%Direct costs per year: SEK 2,000,000 - SEK10,000,000/$ 282,885 - $1,414,427Total costs for project period: SEK 77,741,725/$10,996,000Project period: 1987 -

B) Past Grants**Professor Gustafsson has been a grant holder for the last 35 years. It is an almost impossible work to list them all. This shows the last five years of past grants.

Agency: Swedish Research CouncilI.D.# K2002-03X-02819-33Title: “Mechanism of action of nuclear receptors: biological function of the orphan

receptors LXRalpha and LXRbeta” P.I.: Jan-Åke Gustafsson, M.D., Ph.D., ProfessorPercent effort: 15%Direct costs per year: SEK 1,400,000/ $198,104Total costs for project period: SEK 8,400,000/ $1,188,624Project period: 01/01/2002 – 12/31/2007

Agency: Swedish Cancer SocietyI.D.# 05 0212Title: “The role of estrogen receptor in cancer”P.I.: Jan-Åke Gustafsson, M.D., Ph.D., ProfessorPercent effort: 20%Total costs for project period: SEK 6,900,000/ $976,369Project period: 01/01/2004-12/31/2006

Agency: EUI.D.# FOOD-CT-2003-506143Title: DEVNERTOX “Toxic threats to the developing nervous system: In vivo and in

vitro studies on the effects of mixture of neurotoxic substances potentially contaminating food”

P.I.: Sandra Ceccatelli, M.D., Ph.D., ProfessorRole on project: PartnerPercent effort: 5%Total costs for project period: EUR 240,000/ $324,840 (our part)Project period: 12/01/2003-11/30/2006

Agency: EUI.D.# QLK4-CT-2002-02528Title: BONETOX “Bone development and homeostasis-critical targets in toxicology”P.I.: Helen Håkansson, Ph.D., ProfessorRole on project: PartnerPercent effort: 5%Total costs for project period: EUR 263,813/ $357,071 (our part)Project period: 01/01/2003-12/31/2006

Agency: EU

7


I.D.# QLK4-CT-2002-02221Title: EDERA “Development and implementation of new in vivo and in vitro systems

for the characterization of endocrine disrupters”P.I.: Adriana Maggi, Ph.D., ProfessorRole on project: PartnerPercent effort: 5%Total costs for project period: EUR 172,500/ $233,479 (our part)Project period: 01/01/2003-06/30/2006

Participated in the supervision of the following Ph.D. and M.Sci students to the presentation of their theses

1. Håkan Eriksson: Studies on the metabolism of steroid hormones in rat liver. Thesis, 1971.2. Sven A. Gustafsson: Sexual differentation of corticosteroid metabolism in the rat. Thesis,

1974.3. Åke Stenberg: Mechanisms of sexual differentiation of steroid metabolism in rat liver. Thesis,

1974.4. Magnus Ingelman-Sundberg: Hepatic metabolism of steroid sulphates with special reference

to cytochrome P-450-catalyzed reactions. Thesis, 1975.5. Åke Pousette: Studies on the control of androgen responsiveness in rat. Thesis, 1976.6. Örjan Wrange: Studies on the glucocorticoid receptor in rat liver and the estradiol receptor in

human breast cancer. Thesis, 1977.7. Paul Skett: Hypophyseal control of hepatic steroid metabolism in the rat. Thesis, 1977.8. Anders Berg: Studies on cytochrome P-450-dependent steroid hydroxylations in mammalian

and bacterial systems. Thesis, 1978.9. Peter Ekman: Steroid receptors in the human prostate. Thesis, 1978.10. Jan Carlstedt-Duke: Studies on two hepatic intracellular receptor proteins in the rat: The

glucocorticoid receptor and the 2,3,7,8-tetrachlorodibenzo-p-dioxin receptor. Thesis, 1979.11. Björn Forsgren: Studies on a major protein in the ventral prostate of the rat that interacts with

metabolites of estramustine phosphate and related steroid-cytostatic complexes. Thesis, 1979.

12. Erik Dahlberg: Studies on steroid hormone receptors in rat skeletal muscle. Thesis, 1980.13. Zhao-Ying Yu: Studies of steroid hormone receptors in brain. Thesis, 1981.14. Gunnar Norstedt: Regulations of prolactin and estrogen receptors in rat liver. Thesis, 1981.15. Tiiu Hansson: Studies on hepatic steroid metabolism in rainbow trout, Salmo gairdneri.

Thesis, 1981.16. Livia Alm: The effect of fermentation on nutrients in milk and some properties of fermented

liquid milk products. Thesis, 1982.17. Rune Toftgård: Xylene, an inducer of hepatic cytochrome P-450 and xenobiotic

biotransformation in the rat. Thesis, 1982.18. Joseph J. Rafter: Role of the intestinal microflora in the formation of sulphur-containing

conjugates of xenobiotics. Thesis, 1982.19. Tapio Haaparanta: Isolation of subcellular fractions from the rat ventral prostate and

characterization of prostacic cytochrome P-450. Thesis, 1983.20. Agneta Mode: Growth hormone - a regulator of the sexually differentiated steroid metabolism

in rat liver. Thesis, 1983.21. Tönu Saartok: Steroid receptors as prediction of direct hormonal response in human and

rabbit skeletal muscle. Thesis, 1983.22. Sam Okret: Immunochemical studies on glucocorticoid receptor structure and function.

Thesis, 1983.

8


23. Lorenz Poellinger: Characterization of the receptor for 2,3,7,8-tetrachlorodibenzo-p-dioxin in rat liver. Thesis, 1985.

24. Catriona MacGeoch: Characterization and growth hormone regulation of sexually differentiated cytochrome P-450 isozymes in rat liver. Thesis, 1986.

25. Johan Lund: Methyl sulfone metabolites of polychlorinated biphenyls: studies on the mechanism of accumulation in lung. Thesis, 1986.

26. Ann-Charlotte Wikström: Production and use of monoclonal antibodies against the glucocorticoid receptor. Thesis, 1986.

27. Agneta Blanck: The hypothalamo-pituitary-liver axis - a possible determinant of sex differences in chemical hepatocarcinogenesis in the rat? Thesis, 1987.

28. Peter Söderkvist: Studies on regulation and enzymatic activity of drug-induced cytochrome P-450 in rat ventral prostate. Thesis, 1987.

29. Mikael Gillner: Studies on the receptor for 2,3,7,8-tetrachlorodibenzo-p-dioxin in the rat. Thesis, 1988.

30. Lennart Möller: 2-Nitrofluorence, in vivo metabolism and assessment of cancer risk of an air pollutant. Thesis, 1988.

31. Mikael Brönnegård: Studies on the structure and function of the human and the rat glucocorticoid receptor. Thesis, 1988.

32. Bolette Husman: Characterization of the somatogenic receptor in rat liver. Thesis, 1988.33. Sam Törnquist: Uptake, metabolism and DNA-binding of the chemical carcinogens benzo(a)-

pyrene and 2-nitrofluorene in the rat lung. Thesis, 1989.34. Marc Denis: The non-activated glucocorticoid receptor: structure and activation. Thesis, 1989.35. Lars-Arne Haldosén: Characterization of the prolactin receptor in rat liver. Thesis, 1989.36. Anders Berkenstam: Estrogen and progesterone receptors in human breast cancer cells:

studies on mechanisms for steroid dependent versus constitutive gene expression. Thesis, 1989.

37. Eva Övervik: Formation and biological effects of cooked-food mutagens. Thesis, 1989.38. Yu Dong: Transcriptional and post-transcriptional regulation of gene expression: Studies on

glucocorticoid receptor and alcohol dehydrogenase. Thesis, 1990.39. Pia Lindeskog: Effects of diet on rat small intestinal cytochrome P-450 IA1. Thesis, 1990.40. Scott Cuthill: The mechanism of action of the dioxin receptor. Thesis, 1990.41. Gunnar Johansson: Effects of a shift from a mixed diet to a lactovegetarian diet on some

colon cancer associated characteristics. Thesis , 1990.42. Karin Dahlman-Wright: DNA-binding by the glucocorticoid receptor: a structural and functional

analysis. Thesis, 1991.43. Ann Lidbeck: Studies on the impact of Lactobacillus acidophilus on human microflora and

some cancer-related intestinal ecological variables. Thesis, 1991.44. Carol Cairns: Mechanisms and role of DNA-binding in steroid hormone receptor action.

Thesis, 1993.45. Gunnar Akner: Localization of glucocorticoid receptor (GR) and heat shock protein Mr 90,000

(Hsp90) in mammalian cells. Thesis, 1993.46. Maria Strömstedt: Characterization of cytochrome P450 in rat ventral prostate and brain.

Thesis, 1993.47. Olof Andersson: Structure and function of a Clara cell-specific, PCB-binding protein. Thesis,

1993.48. Per-Erik Strömstedt: Molecular analysis of glucocorticoid receptor-hormone interaction.

Thesis, 1993.49. Anna Wilhelmsson: Mechanism of activation of the dioxin receptor. Thesis, 1993.50. Wilhelm Cairns: A study of mechanisms involved in the control of glucocorticoid receptor

function. Thesis, 1993.

9


51. Anders Ström: Cloning, characterization and regulation of CYP2C genes expressed in rat liver. Thesis, 1994.

52. Johanna Zilliacus: Structural determinants of DNA-binding specificity by the glucocorticoid receptor. Thesis, 1994.

53. Petra Tollet: Growth hormone signal transduction and regulation of CYP2C12 expression in primary rat hepatocytes. Thesis, 1995.

54. Carol Soontjens: Ligands for nuclear receptors development and application of methods for identification. Thesis, 1995.

55. Dezhong Liao: Hormonal regulation of sex differentiated liver carcinogenesis in the rat. Thesis, 1996.

56. Stefan Westin: Regulation of cytochrome P4502C7: Effects of growth hormone and vitamin A. Thesis, 1996.

57. Marika Kleman: Regulation of dioxin receptor function by procarcinogenic food-derived heterocyclic amines and indolocarbazoles. Thesis, 1996.

58. Kaj Grandien: The estrogen receptor gene; promoter organization and expression. Thesis 1996.

59. Magnus Nord: Regulation and function of the Clara cell secretory protein. Thesis 1997.60. Jacqueline McGuire: Mechanism of conditional regulation of the bHLH/PAS dioxin receptor.

Thesis, 1997.61. Yang Yang: The in vivo metabolism of benzo[a]pyrene studied by chromatography in

combination with mass spectrometry. Thesis, 1997.62. Tova Almlöf: Gene regulation by the glucocorticoid receptor: Post-DNA binding mechanisms

of transcriptional activation. Thesis, 1997.63. Heike Hellmold: Toxicological and endocrinological aspects of cytochrome P450 in breast

and lung. Thesis, 1998.64. Thomas Meyer: Mechanism of conditional repression of human osteocalcin gene activity by

glucocorticoids. Thesis, 1998.65. Tony Pircher: Regulation of STAT5 activity by growth hormone. Thesis, 1998.66. Annika Wallberg: Chromatin remodeling complexes involved in gene activation by the

glucocorticoid receptor. Thesis, 1999.67. Ulrika Lind: Functional analysis of ligand recognition by the glucocorticoid receptor. Thesis,

2000.68. Katarina Pettersson: Signal transduction via estrogen receptors (ERs) and estrogen receptor-

related receptors (ERRs). Thesis, 2000.69. Thomas Barkhem: Molecular mechanisms of estrogen/antiestrogen action. M.Sci. thesis,

2000.70. Johan Lidén: Repression of transcription factor NF-B by glucocorticods. A molecular

mechanism for their anti-inflammatory and immuno-modulatory effects. Thesis, 2000.71. Eva Hedlund: Cytochrome P450 in the rat brain: Characterization and regulation. Thesis,

2000.72. Tobias Cassel: Transcriptional regulation of differentiation markers in the distal lung

epithelium – A role for C/EBP factors. Thesis, 2001.73. Sara Windahl: Functions of estrogen receptor in the metabolism of rodent bone. Thesis,

2001. 74. Anette Wärnmark: Molecular mechanisms of gene activation by nuclear receptors and their

associated coregulators. Thesis, 2001.75. Lotta Johansson: Studies on the atypical orphan receptor SHP. Thesis, 2001.76. Zhang Weihua: Estrogen receptor in the urogenital tract of both male and female. Thesis,

2002.77. Tomas Barkhem: Molecular Mechanisms of estrogen and antiestrogen action. Thesis, 2002.

10


78. Hanna Helander: Studies on growth hormone regulation of the CYP2C12 gene in rat liver. Thesis, 2003.

79. Christina Widén: Studies of glucocorticoid receptor interacting proteins. Licentiate thesis, 2003.

80. Anastasios E. Damdimopoulos: Identification and functional characterization of novel thioredoxin systems. Thesis, 2003.

81. Hanne Olsen: STAT5A expression and regulation in mammary epithelial cells. Thesis, 2004.82. Knut R. Steffensen: Putative functions of the liver X receptors in metabolic disorders. Thesis,

2004.83. Malin Hedengran Faulds: Estrogen receptor signaling in mammary epithelial cells. Thesis,

2004.84. Elin Holter: Modulation of nuclear receptor activity by a unique class of corepressors. Thesis,

2004.85. Ann Båvner: Molecular mechanisms of transcriptional repression by the orphan receptor

SHP. Thesis, 2005.86. Waffa Osman: Functional interaction between the glucocorticoid receptor and the proteins

RIP140 and GANP. Masters thesis, 2005.87. Christina Widén: Studies of glucocorticoid receptor interacting proteins. Thesis, 2005.88. Nina Heldring: Molecular basis of estrogen receptor antagonism. Thesis, 2006.89. Sandra Andersson: Nuclear receptor functions in the central nervous system: clues from

knockout mice. Thesis, 2006.90. Otabek Imamov: Role of estrogen receptor beta in mouse ventral prostate with referencies to

human prostatic diseases. Masters thesis, 2006.91. Maria Nilsson: Estrogen and liver X receptors in human disease. Thesis, 2006.92. Hui Gao: Estrogen signaling in metabolic disease; A functional genomics approach. Thesis,

2006.93. Waffa Osman: Modulating of nuclear receptor function by interacting proteins. Thesis, 2007.94. Otabek Imamov: Role of estrogen receptor beta in mouse prostate and bladder with

references to human diseases. Thesis, 2007.95. Lovisa Lundholm: Molecular mechanisms of estrogen action in relation to metabolic disease.

Thesis, 2007.96. Andrea Morani: Role of estrogen receptor beta in Epithelia lacking estrogen receptor alpha

expression. Thesis, 2008.97. Patrick Müller: Hormonal regulation of HES-1 in breast cancer cells. Thesis, 2008.98. Linda Aronsson: Microbial regulation of PPARγ: Nuclear receptor networks important for

colonic homeostasis. Thesis, 2008.99. Johan Hartman: Antiproliferative action of estrogen receptor and HES-1 in breast cancer.

Thesis, 2008.100. Hyun-Jin Kim: LXR and aromatase knock-out mice: Animal models providing insight into

human diseases. Thesis, 2009.

Postdocs and visiting scientists with Jan-Åke Gustafsson

Name From To

1. Cedric Shackleton 1970–1972 2 years2. René-Jean Begue 1971 1 year3. Dominique Bression 1979 1 year4. Marek Snochowski 1979-1982 3 years5. Rabinder Kurl before 1981 2 years

11


6. Peter Hall before 1981 1 year7. Jim Halpert 1982-1984 2 years8. Edward Morgon 1983–1987 4 years9. Rita Hannah 1983 1 year10. Gillian Howell 1984 1 year

11. Tony Wright 1985–1990 5 years12. Constanze Bonifer 1986–1987 1 year13. Ian Callard 1987 1 year14. Paolo Rossini 1985 1 year15. Janet Hapgood 1987 1.5 years

16. John Robertson 870101 90123117. Grant Mason 880101 92022818. Peter Zaphiropoulos 880101 93121519. Hirotoshi Tanaka 890616 91063020. Catherine Legraverend 890801 930731

21. Iain McEwan 891001 97013122. Sarah Ben-Or 900101 90123123. Chris Liddle 900301 91103124. T Nemoto 1988-1989 2 years25. Y Ohara Nemoto 1988-1989 2 years

26. Shin-Ichi Hayashi 1990-1991 2 years27. Kevin Johnson 1990 1 year28. Katerine Gearing 900401 93092429. Martin Göttlicher 910101 94022130. Anke van Eekelen 910201 920131

31. Eric First 910401 94093032. Murray Whitelaw 910401 95123133. Michèle Teboul 920115 94123134. Roger Martin 920127 93123135. Arvydas Kanopka 920215 921215

36. Adrian Wyss 920609 95063037. Helen Osipova 920801 94022838. Henry Barnes 920819 94083139. Olivier Lahuna 920909 96073140. Shigetaka Yoshida 930301 950228

41. Franck Delaunay 930601 951015960117 980228

42. Anja Crickmore 930607 94110143. Franziska Wiebel 931101 95103144. Jaqueline Ford 931108 961031

45. Katrin Hecht 940112 95123146. Carlos Bocos 940117 951231

12


47. Craig Rowlands 940117 95123148. Eckardt Treuter 940413 still49. Greg Lamb 940708 960630

50. Chris Corton 940713 95103151. Dorothee Feltkamp 940801 99053152. Siegfried Alberti 940801 99022853. Hebe Guardiola-Diaz 940819 96081854. Leandro Fernandez 940831 961013

55. George Kuiper 941212 98090156. Alfin Vaz 1995 6 months57. Paula Lapinskas 950417 96022958. Diane DePalo 951002 96022959. Christine Sadek 951118 040331

60. Stéphan Jalaguier 960213 99063061. Martin Holtmann 960311 97013162. Jörg Leers 960401 02103163. Antonio Miranda 960613 04123164. Markko Pelto-Huikko 960801 980731

65. Francis Simon 960916 97063066. Ralf Meyer 961001 97080167. Jane Sohn-Thomsen 961201 04063068. Sari Mäkelä 1997 03053169. Kenichi Mikitani 970121 990531

“ “ 000515 050630

70. Michel Tujague 970414 07053171. Giulia Friso 970513 98013172. José Pedrajas-Cabrero 970609 99063073. Francoise Caira 970701 99061074. Moraima Zelada 970915 001231

75. Jeanette Webster 980301 01043076. Gordon Jamieson 980415 99022877. Gertrud Schuster 980602 04063078. Gary Faulds 980608 00043079. Elwood Jensen 980122 010331

80. Naoya Arai 980615 99093081. Adrian Allan 980901 00083182. Anni Wärri 980901 99083183. Kazuhito Mizuki 981216 01103184. Domingo N-Bosch 990118 000430

85. Jerzy Adamski 990301 00022986. Shigehira Saji 990414 01013187. Guojun Cheng 990914 09021688. Zhao Bian 991001 020731

13


89. Ling Wang 991020 030228

90. Cesare Patrone 000405 01073191. Silke Kietz 000602 03053192. Carola Förster 000703 03043093. Michio Otsuki 000801 03092094. Hideki Sakaguchi 000808 021231

95. Chunyan Zhao 010101 still96. Thomas Stulnig 010302 02033197. Alberto Jiménez Garcia 010702 03063098. Jian Lu 010816 02081599. Gil-jin Shim 010901 051231

100. Andrew Sakko 010903 021231101. Kirsten Remen 010915 still102. Qing Hong Zhang 011001 020630103. Jason Matthews 011010 060413104. Didier Bouton 011030 050630

105. Sabyasachi Sanyal 020520 070331106. Yungshang Piao 020604 040531107. Yoko Omoto 020729 still 108. Yutaka Shoji 020906 040817109. Luisa Helguero 030203 still

110. Jinghong Wan 030314 050313111. Thomas Schwend 040826 080831112. Xiaohua Lou 040901 still113. Osamu Hiraike Wada 050321 070228114. Sebastian Lewandowski 050810 080229

115. Marion Korach-André 050905 still116. Amena Archer 060109 still117. Xiaotang Fan 060203 080801118. Shuyang Yu 060901 070331119. Konstantin Yakimchuk 060918 090101

120. Punga Tanel 061001 070114121. Ivan Nalvarte 061101 still122. Yawen Liu 070122 080118123. Rodrigo Barros 070305 090201124. Knut Steffensen 070301 still

126. Paloma Alonso-Magdalena070604 090101127. Nobuhiro Sugiyama 070701 090401128. Nicolas Venteclef 080107 still129. Tassos Damdimopoulos 080211 still130. Yongwen Chen 080925 090201

14


Scientific Leadership Profile:

As is evident from other material presented in this application, we have contributed significantly to the development of the field of nuclear receptors since the 1970íes. Our discoveries include early demonstration of the three-domain structure of nuclear receptors, specific binding of nuclear receptors to DNA, discovery of steroid response element, cloning of the first nuclear receptor fragment, first determination a 3-D structure of a nuclear receptor (the DNA binding domain of the glucocorticoid receptor), discovery of the first physiological ligand of a nuclear receptor (fatty acids for the peroxisome proliferator activated receptor alpha), discovery of liver X receptor beta (LXRβ), discovery of estrogen receptor beta (ERβ) and unravelling of some of their their functions.

All of the above achievements represent breakthrough events which have significantly impacted upon both the nuclear receptor field as well as neighbouring disciplines. For instance, our demonstration of specific DNA binding of the glucocorticoid receptor helped to develop the enhancer concept and initiated a more molecular phase in the field of nuclear receptors. Our finding of fatty acids as activators of peroxisome proliferator activated receptor alpha helped to bring nutrition closer to endocrinology, thereby being perhaps one of the first examples of molecular nutrition research. Our discovery of ERβ has meant a paradigm shift in our understanding of estrogen signaling, has stimulated pharmaceutical science to develop novel ER isoform specific drugs with broad indications for use against various diseases and has had major impact on the toxicological field of endocrine disruption with particular emphasis on the risk assessment of environmental exposure to xenoestrogens.

Our research achievements have been very well received by the scientific community. I have so far been cited 59 941 times. I have received numerous international awards and distinctions, e g Fogarty Scholar NIH 1999; Foreign Honorary Member of the American Academy of Arts and Sciences 2000; European Medal, British Society for Endocrinology 2000; Lorenzini Gold Medal, Lorenzini Foundation 2001; Foreign Honorary Member of the US National Academy of Sciences 2002; Fred Conrad Koch Award (Endocrine Society USA) 2002; Bristol- Meyers Squibb/Mead Johnson Award for Nutrition Research 2004; Descartes Research Prize for excellence in scientific collaborative research 2005; Honorary Professor at the University of Chongquin, China 2007; Honorary doctor in Medicinal and Pharmaceutical Chemistry at the University of Milan 2008; Honorary Professor at the University of Beijing 2008.

As is evident from other parts of this application we have obtained substantial funding from EU, eg for the NoE CASCADE (for which I am coordinator) as a further sign of the good international reputation of our research group.

All our scientific work has been done in parallel with our building up of the medical research centre, Novum, at the South Campus of the Karolinska Institutet in Huddinge in South Stockholm. The vision of this endeavour has been the integration of preclinical research (e g our own work) and clinical research in a new type of academic environment with small physical distances between the different competencies. With this goal in mind we created Novum, a new building encompassing approximately 500 000 sq feet of research laboratories and offices, side by side with Huddinge University Hospital at South Karolinska Institutet. As the first tenants, we moved into Novum in 1990. This was about ten years after our research group had moved (1981) from the North Campus of the Karolinska Institutet in Solna to the South Campus. During these ten years (1981–1990) we established three research centres, Centre for Biotechnology,

15


Centre for Nutrition and Toxicology and Centre for Structural Biochemistry, financed by the Stockholm County Council, i.e. the regional parliament of Stockholm, responsible for health care and regional planning in Stockholm. In addition, we founded KaroBio AB, an SME with the business idea of developing nuclear receptor targeted drugs. The three centres and KaroBio moved into Novum in 1990.

The creation of KaroBioAB (a nuclear receptor oriented biotech company based in Novum) almost 20 years ago represented new thinking by bringing a commercial enterprise into an academic environment. The ideology behind was the insight that the only way to bring advances at the lab bench to the bed of the patient is via patenting and commercialisation. At the time, this idea was not uncontroversial but today it is undisputed and, indeed, heavily supported by the European Union.

Since about seven years we have actively pursued the next phase of making the South Campus of the Karolinska Institutet into a world renowned research cluster, namely the establishment of Novum BioCity, a new building side by side with Novum. Novum BioCity aims at further integration of preclinical and clinical research, medical and technological research, as well as academic and commercial research. I have recently officially been assigned by President Harriet Wallberg-Henriksson the task to plan and overlook the scientific activities of Novum BioCity.The aim is to create a world renowned research centre with creative and novel contact surfaces between basic and clinical research, between medical and technological research and between academic and commercial research.

One important motivation I have had to engage myself in these “institution-building” activities has been to build up a critical mass of young (and senior) scientists within the field of molecular and applied endocrinology, with particular emphasis on nuclear receptors. As also stated elsewhere in this application, I have participated in the supervision of 98 PhD students to the presentation of their theses as well as supervised 129 postdocs/visiting scientists. Of these 21 have become full professors at different universities around and outside Europe (Rune Toftgård, Lorenz Poellinger, Jan Carlstedt-Duke, Johan Lund, Örjan Wrange, Magnus Ingelman-Sundberg, Jim Halpert, Eckardt Treuter, Agneta Mode, Peter Ekman, Håkan Eriksson, Sam Okret, Åke Pousette, Gunnar Norstedt, Joseph Rafter, Lennart Möller, Anthony Wright, Peter Zaphiropoulos, Shin—Ichii Hayashi, Martin Göttlicher, and Sari Mäkelä).I believe that these facts constitute good evidence of our efforts and ability to inspire younger researchers towards high quality research.

Invited lectures at international meetings:

1. 3rd Int. Congress of Hormonal Steroids, Hamburg, West Germany: "The role of the intestinal microflora in steroid metabolism". September 1970.

2. The Royal Society Meeting, London, UK: "Steroids in meconium and faeces from newborn infants". 1972.

3. The Journal of Steroid Biochemistry Meeting, Paris, France: "Sexual Differentiation of Hepatic Steroid Metabolism in the Rat". April 1974.

16


4. III Bile Acid Meeting on Advances in Bile Acid Research, Freiburg i. Br., West Germany: "Causes of differences between germfree and conventional rats in liver microsomal metabolism of steroids". September 1974.

5. Int. Congress of Hormonal Steroids, Mexico: "Neonatal androgenic programming of hepatic steroid metabolism in rats". September 1974.

6. Meeting of the Journal of Steroid Biochemistry, Paris, France: "Programming and differentiation of rat liver enzymes". 1976.

7. Int. Meeting on Progesterone Receptors in Normal and Neoplastic Tissues, Montreal, Canada: "Progestin receptor in endometrial carcinoma".1976.

8. 568th Meeting of the Biochemical Society in Aberdeen on Steroid Binding and Oligomeric Proteins, Aberdeen, Scotland: "Glucocorticoid-receptor interactions in rat liver". 1976.

9. III Int. Symposium on Microsomes and Drug Oxidations, Berlin, West Germany: "Studies on a cytochrome P-450-dependent hydroxylase system active on steroids in Bacillus megaterium". 1976.

10. Fogarty Conference on Neonatal Hepatitis and Biliary Atresia, Bethesda, USA: "Steroid metabolism in the fetal and perinatal period". March 1977.

11. Int. Symposium on Hormones and Brain Development, Berlin, German Democratic Republic: "Central control of a cytochrome P-450-dependent steroid hydroxylase in rat liver". 1978.

12. Fogarty Conference on Hormones and Cancer, Bethesda, USA: "Estradiol receptor analysis in human breast cancer tissue by isoelectric focusing in polyacrylamide gel". March 1978.

13. Scientific Conf. on Cytochrome P-450: Structural and Functional Aspects, Eberswalde, German Democratic Republic: "Pituitary control of hepatic steroid metabolism". July 1978.

14. Nobel Symposium on Central Regulation of the Endocrine System, Stockholm, Sweden: "Sexual differentiating actions of steroids on the hypothalamo-pituitary-liver axis". 1979.

15. IV Int. Symposium on Microsomes, Drug Oxidations and Chemical Carcinogenesis, Ann Arbor, USA: "Characterization of a steroid-hydroxylating cytochrome P-450 of bacterial origin". 1979.

16. Workshop of the Society of Urologic Oncology and Endocrinology: Steroid Receptors, Metabolism and Prostatic Cancer, Amsterdam, The Netherlands: "On the presence of a major protein, prostatic secretion protein or estramustine-binding protein, in the rat ventral prostate and in the human prostate". April 1979.

17. Int. Symposium on the Biochemistry, Biophysics and Regulation of Cytochrome P-450, Stockholm, Sweden: "The hypothalamo-pituitary-liver axis: a novel regulatory system in the control of cytochrome P-450". 1980.

18. Int. Meeting on Endocrines and the Environment, Morristown, USA: "Role of the hypothalamo-pituitary-liver axis in sex differences in susceptibility of the liver to toxic agents". 1980.

17


19. Int. Workshop on Nutrition and Cancer, Cambridge, UK: "The effect of intestinal microflora on the enterophepatic circulation of mercapturic acid pathway metabolites". July 1980.

20. Int. Meeting on Steroid Hormone Regulation of the Brain, Stockholm: "Studies on the glucocorticoid receptor". October 1980.

21. Int. Meeting on the Prostatic Cell: Structure and Function, Buffalo, USA: "Induction of cytochrome P-450 and metabolic activation of mutagens in the rat ventral prostate". 1981.

22. Int. Symposium on Nutrition and the Intestinal Flora, Saltsjöbaden, Sweden: "Metabolism of steroid hormones in germfree and conventional rats". June 1981.

23. V Int. Symposium on Microsomes and Drug Oxidations, Tokyo, Japan: "Central control of sexual differentiation of hepatic steroid metabolism in the rat". July 1981.

24. II Int. Meeting on Gene Regulation by Steroid Hormones, Detroit, USA: "Functional analysis of the glucocorticoid receptor by limited proteolysis". September 1981.

25. Int. Symposium on Corticosteroid Treatment in Allergic Airway Diseases, Copenhagen, Denmark: "Glucocorticoid-binding proteins in rat liver". October 1981.

26. Int. Symposium on Medroxyprogesterone Acetate, Geneva, Switzerland: "The mechanism of hormone action". February 1982.

27. First American-Swedish Workshop on Individual Susceptibility to Genotoxic Agents in the Human Population, Research Triangle Park, USA: "On the possible significance of TCDD receptor based assays in attempts to estimate environmental health hazards". May 1982.

28. Serono Symposium No 51 on The Endocrines and the Liver, Rome, Italy: "Studies on the hypothalamo-pituitary-liver axis: a novel concept in regulation of steroid and drug metabolism". 1982.

29. First European Congress on Cell Biology, Paris, France: "Isoelectric focusing and enzyme-linked immunosorbent assay of steroid hormone receptors". July 1982.

30. Int. Symposium on Development Pharmacology, Toronto: "Growth hormone: a regulator of the sexually differentiated steroid metabolism in rat liver". October 1982.

31. Meeting of the Journal of Steroid Biochemistry, Paris, France: "Regulation of sexually dimorphic hepatic steroid metabolism by the somatostatin-growth hormone axis". 1982.

32. Int. Meeting on Extrahepatic Drug Metabolism and Chemical Carcinogenesis, Stockholm, Sweden: "Soluble receptor proteins in control of gene expression". May, 1983.

33. Int. Symposium on Hormones and Cancer, Buenos Aires, Argentina: "On the use of antibodies in studies on glucocorticoid receptor structure". May, 1983.

34. II Int. Congress on Hormones and Cancer, Monte Carlo, Monaco: "Studies of steroid hormone receptors in brain". September, 1983.

35. Nobel Symposium on Steroid Hormone Receptors: Structure and Function, Karlskoga, Sweden: "On the use of poly- and monoclonal antibodies in studies on the structure and function of the glucocorticoid receptor". September, 1983.

18


36. Int. Symposium on the Regulation of Androgen Action, Montreal, Canada: "Characterization of prostatic cytochrome P-450". June, 1984.

37. IX Int. Congress of Pharmacology, London, UK: "Recent studies on the mechanism of action of glucocorticoids". August, 1984.

38. Meeting of the International Union of Physiological Sciences, Jerusalem, Israel: "New insights into the mechanism of glucocorticoid hormone action". August, 1984.

39. Int. Symposium on Diet and Prevention of Coronary Heart Disease and Cancer, Stockholm, Sweden: "Metabolism of xenobiotic compounds". October, 1984.

40. Argenteuil Symposium: The Role of Receptors in Biology, Brussels, Belgium: "Purification and DNA binding of mammalian glucocorticoid receptor". October, 1984.

41. Int. Meeting on P-450 Genes and their Regulation, Airlie, USA: "Growth hormone regulation of sex-specific hepatic cytochrome P-450 isozymes". April, 1985.

42. GREMI Symposium: Glucocorticoides aujourd'hui, Paris, France: "Glucocorticoid receptor-DNA interactions". May, 1985.

43. IX Nobel Conference on Thioredoxin and Glutaredoxin Systems - Structure and Function, Lidingö, Sweden: "Regulation, structure and function of the glucocorticoid receptor". May, 1985.

44. 7th Int. Symposium of the Journal of Steroid Biochemistry on Recent Advances in Steroid Biochemistry, Seefeld, Austria: "Structure and tissue localization of the glucocorticoid receptor". June, 1985.

45. 6th Int. Symposium on the Biochemistry of Exercise, Copenhagen: "Characterization and regulation of growth hormone receptor in rat liver". June, 1985.

46. 3rd ECP Symposium on Diet and Human Carcinogenesis, Aarhus, Denmark: "Naturally occurring carcinogens protective factors". June, 1985.

47. IV Int. Conf. on Environmental Mutagens; Satellite Meeting Genetic Toxicology of the Diet, Copenhagen: "Mutagens formed in the gastro-intestinal tract". June, 1985.

48. SEPCR Congress on Clinical Applications of Corticosteroids, The Hague, The Netherlands: "Mechanisms of action of glucocorticosteroids at the subcellular level". June, 1985.

49. Gordon Conference on Hormone Action, Kimball Union, New Hampshire, USA: "Glucocorticoid regulated genes". August, 1985.

50. 5th Int. Conference on Biochemistry, Biophysics and Induction of Cytochrome P-450, Budapest, August 1985: "Biochemical and biophysical characterization of the TCDD receptor - a comparison to steroid hormone receptor". August, 1985.

51. 3rd Meadow Brook Conference on the Molecular Mechanism of Steroid Hormone Action, Rochester, USA: "Mechanism of sex differentiation of rat liver". September, 1985.

52. Int. Symposium on Monoclonal Antibodies: Basic Principles, Experimental and Clinical Applications in Endocrinology, Florence, Italy: "Monoclonal antibodies to glucocorticoid receptors". October, 1985.

19


53. First Int. Congress on Cancer and Hormones: Endocrinology and Malignancy: Basic and Clinical Issues, Rome, Italy: "Regulation of glucocorticoid receptor". April, 1986.

54. Second Int. Symposium in Hematology and Oncology organized by The Hematology Collaborating Group at the Karolinska Hospital under the auspices of the Karolinska Institute in honour of Prof. J.G. Waldenström: Immunoglobulins and Growth Factors in Hematology and Oncology, Stockholm: "Glucocorticoid mechanism of action: monoclonal antibodies as experimental tools". May, 1986.

55. NATO Advanced Research Workshop on Plant Hormone Receptors, Bonn: "Mechanism of action of glucocorticoid hormones". August, 1986.

56. Satellite Symposium of 7th International Congress on Hormonal Steroids: Anti-Steroids, Marbella, Spain: "Gene expression and hormone receptors". September, 1986.

57. 59th Annual Meeting of the Japanese Biochemical Society, Osaka: "Regulation and expression of cytochrome P-450 in liver and brain". September, 1986.

58. The Molecular Biology of Drug Metabolizing Enzymes, London: "Hormonal control of sex specific cytochrome P-450 isozymes in rat liver". December, 1986.

59. UCLA Symposia on Molecular and Cellular Biology: Steroid Hormone Action, Park City, Utah, USA: "Structure, function and localization of the glucocorticoid receptor". January, 1987.

60. 2nd International Workshop on P450 Gene Regulation, Airlie, Virgina, USA: "Cloning and regulation of cytochrome P45015ß and P45016a in rat liver". April, 1987.

61. 7th International Symposium on Microsomes and Drug Oxidations, Adelaide, Australia: "Role of endocrine factors in the regulation of cytochrome P-450 expression". August, 1987.

62. 625th meeting of the Biochemistry Society on "Molecular Biology of Hormone Action" Dublin, Irland: "Mechanism of Action of Glucocorticoid Hormones". September, 1987.

63. 8th European Winter Conference on Brain Research, Tignes/Val d'Isere, France: "On the Expression and Regulation of the Glucocorticoid Receptor". March, 1988.

64. "Glucocorticoids - from cloning to clinic", Edinburgh, England. May, 1988.

65. 8th International congress of Endocrinology, Kyoto, Japan: "The dioxin and glucocorticoid receptors: two similar gene regulatory proteins". July, 1988.

66. 6th Biophysics-Biochemistry of cytochrome P-450 congress, Vienna, Austria: "Glucocorticoid & dioxin receptors - a comparison". July, 1988.

67. Fourth International Symposium on Cellular Endocrinology, Lake Placid, USA: "Structure, function and regulation of the glucocorticoid receptor". August, 1988.

68. NATO Advanced Research Workshop on "Molecular Mechanisms and Consequences of Activation of Hormone and Growth Factor Receptors, Nafplion, Greece: "Glucocorticoid receptor". September, 1988.

69. Molecular biology in drug design and in drug production, Uppsala, Sweden: "Role of ligand binding in glucocorticoid receptor function". December, 1988.

20


70. 9th International symposium of the Journal of Steroid Biochemistry, Las Palmas, Canary Islands, Spain: "Expression and structure of the Glucocorticoid Receptor". May, 1989.

71. Biochemical Society meeting, Host Colloquium on "Development of Mixed-Function Oxidases", Surrey, UK: "The cytochromes P-450 of brain and their role in the metabolism of neurosteroids". July, 1989.

72. Molecular Biology and Pathophysiology of Hormone Regulation and Actions, Heidelberg, West Germany: "Expression, structure and regulation of the glucocorticoid receptor". July, 1989.

73. FASEB Summer Research Conference: "Nutrients, Gene Expression, and Cancer", Copper Mountain, Colorado, USA: "Mechanisms of GH effects on liver cytochrome P-450 isozymes". July, 1989.

74. NATO Advanced Study Institute on "Molecular aspects of monooxygenases and bioactivation of toxic compounds", Cesme, Izmir, Turkey: "Hormonal Regulation of P-450 Gene Expression" and "Xenobiotic Regulation of P-450 Gene Expression". September, 1989.

75. Fourth International Symposium in Hematology and Oncology, Stockholm, Sweden: "Nutrition and cancer". September, 1989.

76. Steroid Receptors, Transcription Factors, and Gene Expression, San Diego, USA: "Mechanisms of steroid nonresponsiveness in mutant cell lines". February, 1990.

77. NORDTOX-90, 1st Nordic Conference of Toxicology and 8th Annual Meeting of Nordic Environmental Mutagen Society, Beito, Norway: "Mechanism of dioxin regulation of cytochrome P-450". March, 1990.

78. Berzelius symposium, The Swedish Society of Medicine, Stockholm, Sweden: "Ligand-steroid receptor interactions". March, 1990.

79. Scandinavian Physiological Society Meeting, Lund, Sweden: "On the use of molecular biology in endocrinology". May, 1990.

80. VIIIth International Symposium Microsomes and Drug Oxidations, Karolinska Institutet, Stockholm, Sweden: "Receptor-mediated regulation of gene expression". June, 1990.

81. Eighth international conference on Methods in protein sequence analysis, Kiruna, Sweden: "Steroid receptor-DNA interactions". July, 1990.

82. NATO ASI on Biological Signal Transduction, Spetsai, Greece: "Steroid Receptors I: General background, steroid structure and metabolism, purification and cloning of steroid receptors, members of the steroid receptor supergene family". "Steroid receptors II: Regulation of expression of the glucocorticoid receptor (GR) gene. Bacterial expression of the DNA binding domain DBDr) of GR. The three-dimensional structure of the DBDr-DNA complex". August, 1990.

83. First Düsseldorf Symposium on Immunotoxicology: Molecular Mechanisms of Dioxin Action on Cell Growth and Differentation, Düsseldorf, Germany: "TCDD receptor: physicochemical characteristics and its significance for toxicological effects". October, 1990.

84. Hepatic Metabolism and Disposition of Endo- and Xenobiotics, Freiburg, Germany: "Comparative Studies of the Glucocorticoid and TCDD-Receptors". October, 1990.

21


85. Biological Basis For Risk Assessment of Dioxins & Related Compounds, Banbury, USA: "Molecular biology and physiology of TCDD receptor - DNA interactions". October, 1990.

86. Symposium in honour of Professor Minor J. Coon, Ann Arbor, USA: "The glucocorticoid receptor: Structure, function and regulation". November, 1990.

87. Xenobiotics and Cancer: Implications for chemical carcinogenesis and cancer chemotherapy, Tokyo, Japan: "The molecular biology of the glucocorticoid and dioxin receptors". November, 1990.

88. First International symposium on hormonal carcinogenesis, Cancun, Mexico: "Sexual dimorphism of hepatic steroid hormone metabolism and its significance for chemical hepatocarcinogenesis". March, 1991.

89. Cytochrome P450: Advances and prospects, Atlanta, USA: "Regulation of rodent cytochrome P-450 gene expression by steroid hormones". April, 1991.

90. 10th International Symposium of the Journal of Steroid Biochemistry and Molecular Biology, Paris, France: "Glucocorticoid receptor: structural and functional studies". May, 1991.

91. 7th International Conference "Biochemistry & Biophysics of Cytochrome P-450; Structure & Function, Biotechnological & Ecological Aspects", Moscow, U.S.S.R: "Molecular mechanisms in regulation of cytochrome P-450 gene expression". August, 1991.

92. Gordon Conference on Hormone Action, New Hampshire, USA: "Structure and Function of the Three Domains of the Glucocorticoid Receptor". August, 1991.

93. Arolla Workshop 1991 "From Receptor to Gene", Arolla, Switzerland: "Structure and Function of the Three Domains of the Glucocorticoid Receptor". August, 1991.

94. International Symposium on A Molecular View of Steroid Biosynthesis and Metabolism, Jerusalem, Israel: "Hepatic steroid metabolism is controlled by the sexually dimorphic pattern of growth hormone secretion in both normal and dwarf rats". October, 1991.

95. European Research Conference on "Mechanism in Toxicity", Klingenthal, Alsace, France: "TCDD receptor(s) and their relevance for carcinogenesis". November, 1991.

96. Keystone Symposia on Molecular and Cellular Biology, Steroid/thyroid receptor gene super family, Tamarron, Colorado, USA: "Structural and functional studies on the glucocorticoid receptor". February, 1992.

97. Centre de Recherche du Chul, Québec, Canada: "On the structure and function of the glucocorticoid receptor". May, 1992.

98. Wallenberg Symposium, The Metabolic syndrome, Gothenburg, Sweden: "Mechanism of action of steroid hormones". May, 1992.

99. NOMBA, Progress in Molecular Biology, Helsinki, Finland: "Molecular biology of the glucocorticoid receptor". May, 1992.

100. Endocrine Society Meeting, San Antonio, Texas, USA: "Overexpression in Bacteria, Yeast and Eukaryotic Cells of Steroid Receptors and Steroid Receptor Domains". June, 1992.

101. 9th International Symposium on Microsomes and Drug Oxidations, Jerusalem, Israel: "Mechanisms of regulation of expression of hepatic cytochrome P-450". July, 1992.

22


102. 5th International congress on Cell Biology, Madrid, Spain: "Functional analysis of the three domains of the glucocorticoid receptor". July, 1992.

103. NATO/FEBS on New Developments in Lipid-Protein Interactions and Receptor Function, Spetsai, Greece: "Determinants for DNA binding site recognition by the glucocorticoid receptor". "Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor". August, 1992.

104. 11th International Conference on Comparative Physiology, The Differences between the sexes, Crans-sur-Sierre, Switzerland: "Why are there male and female livers and kidneys?". September, 1992.

105. The University of Oslo, Jahreföreläsning, Oslo, Norge: "The functional architecture of the glucocorticoid receptor". September, 1992.

106. Keith Harris lecture, Australian Endocrine Society, Adelaide, Australia: "The molecular biology of the glucocorticoid receptor". October, 1992.

107. Invited lecturer at Collége de France, Paris, France: "Functional architecture of the glucocorticoid receptor". October, 1992.

108. Invited lecturer at University of California, Berkeley, USA: "Functional architecture of the glucocorticoid receptor". October, 1992.

109. The Karolinska-Minnesota Frontiers of Medicine Symposium, Minnesota, USA: "Functional architecture of the glucocorticoid receptor". October, 1992.

110. American association for the study of liver diseases, Chicago, Illinois, USA: "Hormonal regulation of Cytochromes P-450". November, 1992.

111. The 23rd International Symposium of the Princess Takamatsu Cancer Research Fund, Tokyo, Japan: "Induction of cytochrome P450 1A isozymes by heterocyclic amines and other food derived compounds". November, 1992.

112. Functions and structures of genes and proteins, Mariehamn, Åland: "Structure and function of the glucocorticoid receptor". November, 1992.

113. Perspectives in Nutrition Research Towards Year 2000, Oslo, Norway: "Molecular Nutrition: Regulation of Gene Expression by Fatty Acids". December, 1992.

114. Receptor Mediated Biological Processes: Implication for Evaluating Carcinogens, Austin, Texas. December, 1992.

115. Symposium on Fat and Gene Expression, New Orleans, U.S.A.: "Fatty acid activation of the peroxisome proliferator activated receptor (PPAR), a member of the nuclear receptor supergene family".March, 1993.

116. Biochemistry, Endocrinology and Pharmacology of Nuclear Receptors, Marburg, Germany: "Fatty acid activation of PPAR". May, 1993.

117. 11th International Symposium of The Journal of Steroid Biochemistry and Molecular Biology "Recent advances in steroid biochemistry and molecular biology", Seefeld, Austria: "Structure and function of the glucocorticoid receptor". May/June, 1993.

118 The Karolinska Institute and the Summer University of Southern Stockholm, "Understanding Signal Transduction", Stockholm, Sweden: "Steroid/thyroid hormone receptors". June, 1993.

23


119. 18th International Congress of Chemotherapy, "Principles of endocrine treatment of cancer - basic aspects and clinical regimens", Stockholm, Sweden: "Basic aspects on steroid hormone actions". June, 1993.

120. International Symposium on Antioxidants and Disease Prevention, Biochemical, Nutritional, and Pharmacological Aspects, Stockholm, Sweden: "Control of Gene Expression by Fatty Acids and Retinoids". June/July, 1993.

121. 22nd Meeting of the Federation of European Biochemical Societies, Stockholm, Sweden: "The functional architecture of the glucocorticoid receptor". July, 1993.

122. Second Asia-Pacific Symposium on Environmental and Occupational Health – Toxico-logical Studies, Kobe, Japan: "Mechanisms of Induction of Cytochrome P450 by Environmental Agentsparticipation of Ligand Activated Transcription Factors from Two Different Gene Families". July, 1993.

123. 5th International CBT Symposium, "Intracellular hormone receptors and ligand-dependent transcriptional regulation", Stockholm, Sweden: "Activation of PPAR by fatty acids". September, 1993.

124. Instituto Juan March de Estudios e investigaciones, Centre for International Meetings on Biology. Workshop on Neuroendocrinology of Growth. Madrid, Spain: "Mechanisms of sex differentiation and growth hormone regulation of hepatic P450 genes in the rat". October, 1993.

125. 8th International Conference on Cytochrome P450, Lisbon, Portugal: "Mechansims of sex differentiation and growth hormone regulation of hepatic P450 genes in the rat". October, 1993.

126. 4th International Thyroid Symposium on "Genetic defects of thyroid and steroid hormons receptors: molecular basis and clinical expression", Ulm, Germany: "Thyroid and steroid hormone receptor family". November, 1993.

127. Biochemical Society Meeting 649, London, U.K.: "Receptor-mediated regulation of drug metabolising enzymes". December, 1993.

128. Norsk Biokjemisk Selskaps 30 årsjubileumsmöte: "Novel aspects on ligand activated transcription factors". January, 1994.

129. Keystone Symposia on Molecular and Cellular Biology, Taos, New Mexico: "The dioxin receptor - another ligand activated transcription factor". February, 1994.

130. Symposium on Eukaryotic Gene Expression and Regulating Signals, New York: "Functional architecture of the glucocorticoid receptor and characteristics of some novel members of the steroid/thyroid hormone receptor super family". April, 1994.

131. The Lundberg Symposium, Gothenburg: "Nuclear receptors - an expanding super gene family". May, 1994.

132. Nordic Meeting on Biochemical and Medical Aspects of Lipid Metabolism in Peroxisomes and Mitochondria, Huddinge, Sweden: "Activation of the PPAR". May, 1994.

133. The First International Conference on Steroids and Bone, Florence, Italy: "The functional architecture of the glucocorticoid receptor". May, 1994.

24


134. United European Gastroenterology week, Oslo, Norway: "Fatty acid control of gene expression via a member of the nuclear receptor supergene family (PPAR)". June, 1994.

135. XIIth International Congress of Pharmacology, Montréal, Québec, Canada: "Fatty acid activation of PPAR". July, 1994.

136. 10th International Symposium on Microsomes & Drug Oxidations, Toronto, Canada: "Functional analysis of flanking sequences of sex-specific P-450 genes expressed in rat liver". July, 1994.

137. Second International Symposium on Hormonal Carcinogenesis, Novum, Stockholm: "Novel Aspects on Ligand Activated Transcription Factors in Control of Cytochrome P-450". July, 1994.

138. NATO Advanced Study Institute on Molecular Mechansims of Transcellular Signaling: "From the Membrane to the Gene", Spetsai, Greece: "Recent developments in the field of the nuclear receptor supergene family" and "The dioxin receptor - another ligand activated transcription factor". August, 1994.

139. University of Wisconsin-Madison: "Steroid Receptor Superfamily Symposium", Madison, USA: "Functional analysis of the glucocorticoid receptor". September, 1994.

140. IX International Congress on Hormonal Steroids. Dallas, Texas, USA: "Activation of the PPAR". September, 1994.

141. Health Research in Quebec and the world: today and tomorrow: Montréal, Canada: "University-Industry Partnership in Sweden". October, 1994.

142. Worcester Foundation for Experimental Biology, Gregory Pincus Lecture, Shrewsbury, MA, USA: ”Functional organization of the glucocorticoid receptor”. November, 1994.

143. Symposium on "Bridging Basic Science and Liver Disease". Boston, USA: "Mechanisms of growth hormone regulation of sexually differentiated gene expression in the liver". November, 1994.

144. Receptor Mediated Mechanisms in Carcinogenesis, Lyon, France: "Nuclear Receptors and Chemical Carcinogenesis". November, 1994.

145. Keystone Symposia conference on ”Molecular Toxicology”, Keystone, USA: ”Functional architecture of the dioxin receptor/arnt heterodimer”. January, 1995.

146. An AACR Special Conference in Cancer Research: ”Mechanism of action of retinoids, vitamin D, and steroid hormones”, Whistler, British Columbia, Canada: ”Mechanisms of activation and action of PPAR (Peroxisome Proliferator Activated Receptor). January, 1995.

147. Sterling lecture, University of Pennsylvania, Philadelphia, USA: Mechanism of action of the glucocorticoid receptor and of the peroxisome proliferatoractivated receptor (PPAR). March, 1995.

148. EMBO Workshop; Structure and Function of Steroid and Nuclear Receptors, Alghero, Sardinia, Italy: ”Transcriptional activation by the glucocorticoid receptor: Role of the 1

domain”. April, 1995.

149. Pharmacology & Toxicology 50th Anniversary Symposium, Perspectives in the development and safety of new medicines: Biological diversity and structure specificity,

25


Copenhagen, Denmark: ”Mechanisms of Regulation of Drug Metabolizing Enzymes”. May, 1995.

150. 12th International Symposium of the Journal of Steroid Biochemistry and Molecular Biology. ”Recent Advances in Steroid Biochemistry and Molecular Biology”, Berlin, Germany: ”Functional Analysis of the glucocorticoid receptor”. May, 1995.

151. The Aspen Institute: Peroxisomes: Biology and Role in Toxicology and Disease, Aspen, USA: ”Fatty acid signalling of peroxisome proliferator-activated receptor”. June/July, 1995.

152. VII International Congress of Toxicology, Seattle, USA: ”Receptor-mediated toxicity”. July, 1995.

153. Gordon Research Conference on Hormone Action, New Hampshire, USA: ”Functional organization of the dioxin receptor-Arnt complex”. July/August, 1995.

154. The Rank Prize Funds, Mini-Symposium on Nutrients as Regulators (Nutrient Sensing), Grasmere, England: “Regulation of gene expression by fatty acids”. September, 1995.

155. 7th International CBT Symposium: Nuclear Orphan Receptors: Novel Regulators in Physiology and Pathology, NOVUM, Sweden: ”Mechanism of signal transduction of PPAR”. September, 1995.

156. International Symposium on ”DHEA Transformation into Androgens and Estrogens in Target Tissues: Intracrinology”, Québec, Canada: ”Activation of peroxisome proliferator activated receptor (PPAR)”. September, 1995.

157. The European Respiratory Society Annual Congress, Barcelona, Spain: ”Glucocorticoid receptor and transcription factor interactions”. September, 1995.

158. International Symposium on Control Mechanisms of Carcinogenesis, Mainz, Germany: ”Ligand activated transcription factors”. September, 1995.

159. The British Biochemical Society Meeting No. 657, Aberdeen, U.K.: ”Control of gene expression by fatty acids: Role of the peroxisome proliferator activated receptor (PPAR)”. December, 1995.

160. From Invention to Business in Biotechnology, Helsinki, Finland: ”Future scenarios for Biocenters”. January, 1996.

161. Keystone Symposia on Molecular and Cellular Biology, Steroid/Thyroid/Retinoic Acid Gene Family, Lake Tahoe, California: “Cloning of a novel estrogen receptor (ER)”. March, 1996.

162. 2nd Oulu Symposium on Molecular Approaches to Reproductive Health, Oulu, Finland: “Orphan receptors and the search for endogenous ligands”. May, 1996.

163. International Society for Endocrinology, San Francisco, USA: ”Negative cross-talk between the glucocorticoid receptor and other signal transduction pathways”. June, 1996.

164. NATO/FEBS Advanced Study Institute, International Summer School on Molecular Mechanisms of Signaling and Targeting, Spetsai, Greece: ”Orphan nuclear receptors - an exciting development of the steroid/thyroid hormone receptor field” and ”Growth hormone as determinant of hepatic sexual dimorphism”. August, 1996.

26


165. Estrogen and the Blood Vessel Wall Symposium, Seattle, Washington, USA: ”Cloning, Expression and Function of a Novel Estrogen Receptor”. September, 1996.

166. KBF-Symposium Molecuar Targets for Drug Development, Braunschweig, Germany: ”Steroid receptors as molecular targets for drug development”. September, 1996.

167. SPBBM, Colloque GERMÉ, PPARs, nutriments and xenobiotics: as mediators of cell regulation? Dijon, France: “Regulation of PPAR by glucocorticoids and nor-epinephrine”. September, 1996.

168. Tore Nilson symposium on ”Aspects of hormonal regulation of artherosclerosis”, Stockholm: ”Fatty acids and gene regulation”. September, 1996.

169. Steroid Receptor Superfamily Symposium, Madison, USA: ”Characteristics and function of the novel estrogen receptor ”. September, 1996.

170. Deutsche Forschungsgemeinschaft, Symposium Hormonally Active Agents in Food, Kaiserslautern, Germany: ”Novel aspects of environmentally and dietary related ligand activated transcription factors”. October, 1996.

171. University of Leicester, MRC Toxicology Unit, Leicester, U.K.: ”What new can we learn about estrogens in light of the discovery of the novel estrogen receptor ”. February, 1997.

172. Workshop on ”Universities in the Cross-Streams of Globalisation and Information Technology”, Italy: ”Government - Industry - University interaction”. February, 1997.

173. 31st International Meeting of the European Society for Clinical Investigation (ESCI), Kiel, Germany: “Functional characteristics of estrogen receptor ”. March, 1997.

174. NIH, Bethesda, USA: “Recent insights into mechanisms of glucocorticoid action - new crosstalk and coactivators”. April, 1997.

175. Mechanisms of action of estrogens and physiological needs, Chantilly, France: “ and estradiol receptors”. April, 1997.

176. Frontiers in Estrogen Action, Key West, USA: “Identification and characterization of ER”. May, 1997.

177. The paradoxes of growth hormone action, Fiskebäckskil, Sweden: “Free fatty acids - mediators of GH action”. May, 1997.

178. The Endocrine Society 79th Annual Meeting, ENDO ‘97, Minneapolis, USA: ER: a new isoform of the estrogen receptor”. June, 1997.

179. Marabou symposium: Diet and genetic interactions, Stockholm, Sweden: “Fatty acids and gene expression”. June, 1997.

180. Paediatric Endocrinology 1997, Joint Meeting of ESPE and LWPES, in collabora-tion with APEG, JSPE and SLEP, Stockholm, Sweden: “Cloning and function of the novel estrogen receptor ”. June, 1997.

181. Eurotox Congress in collaboration with the Danish Society of Pharmacology and Toxicology, Aarhus, Denmark: “Receptor mediated toxic responses”. June, 1997.

27


182. FEBS Special Meeting, Cell Signalling Mechanisms; from membrane to nucleus, Amsterdam, The Netherlands: “Novel insights into estrogen mechanism of action”. June/July, 1997.

183. XXXIII International Congress of Physiological Sciences IUPS 1997, St. Petersburg, Russia: “Estrogen receptor - tissue distribution and functional properties”. July, 1997.

184. NIEHS Conference on Estrogens in the Environment IV: Linking Fundamental Knowledge, Risk Assessment, and Public Policy, Arlington, Virgina, USA: “Hormone action of a new estrogen receptor: ER-“. July, 1997.

185. Gordon Research Conference on Hormone Action, New Hampshire, USA: “Characterization of a novel estrogen receptor”. July/August, 1997.

186. Gordon Research Conference on Hormonal Carcinogenesis, Tilton, USA: ”Novel insights into the mechanism of action of estrogens in the light of the discovery of a second estrogen receptor gene”. July/August, 1997.

187. 17th International Congress of Biochemistry and Molecular Biology, San Francisco, USA: “Ligand activated transcription factors in control of cytochrome P450”. August, 1997.

188. The fifth CFN Symposium, Effects of Toxicants on Gene Expression and Intracellular Signalling, Saltsjöbaden, Sweden: “Impact of environmental pollutants on nuclear receptors”. September, 1997.

189. Symposium on Phytoestrogen Research Methods, Chemistry, Analysis, and Biological Properties, Tucson, Arizona, USA: ”The estrogen -receptor and its interaction with phytoestrogens”.

190. Workshop on Estrogen Action, New Jersey, USA: ”Expression and Function of ER”. October, 1997.

191. XV Congrès de la Société Francaise d’Endocrinologie, Paris, France: ”Cloning, expression and role of a novel estrogen receptor”. October, 1997.

192. 9th International CBT Symposium, Steroid and Orphan Nuclear Receptors, Stockholm, Sweden: ”OR1 and PPAR - two major regulators of lipid metabolism”. October, 1997.

193. Molecular basis of sex hormone receptor function - New targets for intervention, Berlin, Germany: ”Estrogen receptor ”. October, 1997.

194. EMRC Workshop ”Crosstalk between steroid receptors and other transcription factors: molecular basis for immunomodulatory and anti-inflammatory effects of steroids”, Ottrott, Alsace, France: ”PPAR and OR-1: Two major regulators of lipid metabolism”. November, 1997.

195. Academy of Military Medical Sciences, Beijing, China: “Orphan receptors - a rapidly developing field with nutritional implications”. November, 1997.

196. Receptor Biology Roundtable, Center for Executive Education at Babson College, Massachusetts, USA: ”Estrogen receptor isoforms”. December, 1997.

197. Seminar at CIIT, North Carolina, USA: ”Nuclear receptors as mediators of chemical-induced toxic responses: Mechanism of peroxisome proliferator-activated receptor”. December, 1997.

28


198. Distinguished lecturer seminar, NIEHS, Research Triangle Park, North Carolina, USA: ”The Estrogen Receptor Beta”. December, 1997.

199. AAAS Annual Meeting and Science Innovation Exposition, Philadephila, Pennsylvania: Cochair at the symposium ”Manipulation of Science by Vested Interests: Money and Power versus Public Health”. February, 1998.

200. University of Colorado Health Sciences Center, Department of Pathology, Denver, USA: “Novel developments in nuclear receptors: postreceptor signalling and estrogen receptor ”. February, 1998.

201. Keystone Symposia on Breast and Prostate Cancer, Copper Mountain, Colorado, USA: “Mechanism of Action of Estrogen Receptor ”. February, 1998.

202. Tokyo Medical Association Meeting (Tokyo Society of Medical Science), Tokyo, Japan: “New developments in nuclear receptors: crosstalk, coactivators and orphan receptors”. February, 1998.

203. Symposium for Sex Difference and Similarity Society, Tokyo, Japan: “New developments in nuclear receptors: crosstalk, coactivators and orphan receptors”. February, 1998.

204. International Symposium on Biology of Prostate Growth, Bethesda, Maryland, USA: “Estrogen receptor in prostate”. March, 1998.

205. Estrogens as initiators and promoters in breast and prostate cancer, Chantilly, Virginia, USA: “Structure and properties of estrogen receptor ”. March, 1998.

206. Keystone Symposia on Molecular & Cellular Biology, Nuclear Receptor Gene Family Conference, Lake Tahoe, Nevada: ”Estrogen receptor predicted effects of estrogen”. March/April, 1998.

207. 2nd Congress of Molecular Medicine, Berlin, Germany: ”Biology of the novel estrogen receptor ER”. May, 1998.

208. IV European Congress of Endocrinology, Sevilla, Spain: ”Steroid receptors - New dimensions”. May, 1998.

209. 18th Blankenese Conference, Orphan receptors and novel ligands, Hamburg-Blankenese, Germany: ”OR-1 and peroxisome proliferator-activated receptors (PPAR) - two major regulators of lipid metabolism”. May, 1998.

210. Frontiers in Estrogen Action, Rio Grande, Puerto Rico: ”Signalling via estrogen receptor ”. May, 1998.

211. NFOG ’98, The Federation of Scandinavian Societies of Obstetrics and Gynecology, Århus, Denmark: ”Estrogen receptor : A new dimension in estrogen receptor research”. May, 1998.

212. Nordtox/NordEMS-98, The 5th Nordic Toxicology Meeting, Helsinki, Finland: “In vitro studies for understanding toxic mechanisms in vivo”. May, 1998.

213. European Federation of Endocrine Societies, 2nd Postgraduate Course in Molecular and Cellular Endocrinology, Turku, Finland: “The steroid/thyroid hormone receptor family”. June, 1998.

214. Laboratory Medicine 98, Turku, Finland: “Estrogen Receptor ”. Keynote lecture. June, 1998.

29


215. 3rd International Symposium on Women’s Health and Menopause, Risk Reduction Strategies - Improved Quality of Health, Florence, Italy: “Novel mechanisms of estrogen action” and ”Estrogen receptor - a new hope for tissue specific HRT”. June, 1998.

216. Xth Int. Congress on Hormonal Steroids, Québec, Canada: ”Estrogen receptor - a new dimension in estrogen mechanism of action”. Keynote lecture. June, 1998.

217. Int. Congress of Toxicology, Paris, France: “PPAR activation and its consequences in experimental animals”. July, 1998.

218. Gordon Research Conference, New Hampshire, USA: “Expression and function of the new estrogen receptor: ER”. July, 1998.

219. Int. Congress of Pharmacology, München, Germany: ”Peroxisome proliferator activated receptor or PPAR”. July, 1998.

220. The Society for the Study of Reproduction, Texas, USA: “Physiology and molecular biology of estrogen receptor “. Keynote lecture. August, 1998.

221. NATO/FEBS Advanced Study Institute, International Summer School on Molecular Mechanisms of Transcellular Signalling: From Membrane Receptors to Trancription Factors, Spetsai, Greece: ”Coactivators and corepressors in nuclear receptor function” and ”Novel insights into the role of orphan nuclear receptors”. August, 1998.

222. European Teratology Society, Stockholm: “Basic concepts of hormone-receptor interactions”. September, 1998.

223. 3rd Int. Symp on Hormonal Carcinogenesis, Seattle, Washington, USA: “Estrogen receptor - an important player in estrogen action”. September, 1998.

224. Estrogens and Human Health, Urbana, Illinois, USA: ”Estrogen receptors and ”. October, 1998.

225. Sex-Hormones, Their Receptors and Biological Response, Louisville, Kentucky, USA: “New dimensions in estrogen action: ER”. October, 1998.

226. Steroid hormone action at the turn of the century. Four decades after puff induction by ecdysone, Marburg, Germany: ”Recent paradigm shifts in our understanding of estrogen signalling”. October, 1998.

227. Sex-Steroids and the Somatotropic Axis, La Playa, Naples, Florida, USA: ”Intracellular transacting signals”. October, 1998.

228. Breast and menopause, Wroclaw, Poland: “Estrogen receptor ”. October, 1998.

229. Nuclear Receptors - Minisymposium, Oslo, Norway: “Introduction into the nuclear receptor field”. November, 1998.

230. Sixth Annual Meeting of Japan Hormonal Steroid Society, Osaka, Japan: Keynote Lecture “Estrogen receptor - a new dimension in estrogen mechanism of action”. November, 1998.

231. The first Märta Philipson Symposium in Pediatric Research, Stockholm ”Estrogen receptor : Functional role for a new estrogen receptor in mammalian development”. December, 1998.

30


232. AACR Special Conference on The Steroid Receptor Superfamily, Indian Wells, CA, USA: ”Estrogen receptor - new exciting developments”. January, 1999.

233. 23rd International LOF-symposium on phyto-oestrogens, Gent, Belgium: ”The estrogen receptor and its interaction with phytoestrogens”. January, 1999.

234. ILSI Health and Environmental Science Institute, Nassau, Bahamas: ”Nuclear Receptors”. January, 1999.

235. Endocrine Disruptors, Keystone, Lake Tahoe, USA, February, 1999: ”Properties, distribution & function of ER”. February, 1999.

236. Women’s Health Roundtable, Pasadena, USA: Estrogen receptors and other nuclear receptors”. February, 1999.

237. Estrogen and progesterone receptors and their ligands, Society for Gynecologic Investigation, Atlanta, USA: ”Estrogen Receptors: Alpha and Beta”. March, 1999.

238. The 4th Congress of the European Society for Gynecologic and Obstetric Investigation, Madonna di Campiglio, Italy: ”New dimensions in estrogen mechanism of action offer new hopes for therapy of diseases in the postmenopausal woman”. March, 1999.

239. Frontiers in Estrogen Action, Dana Point, California, USA: ”The nuclear receptors”. April, 1999.

240. 18th Joint Meeting of the British Endocrine Societies, Insulin resistance and cardiovascular disease: mechanisms and consequences, Bournemouth, UK: “Nuclear receptors involved in lipid metabolism: PPAR, ER, OR-1 and RLD-1”. April, 1999.

241. German Society of Endocrinology and German Society of Human Genetics, International Symposium on Breast and Prostate Cancer: Genes, Hormones and the Environment, Casle Elmau, close to Garmisch-Partenkirschen, Germany: ”Recent advances in our understanding of nuclear receptor action”. April, 1999.

242. Keystone Symposium on The PPARs: Transcriptional links to obesity, diabetes and cardiovascular disease, Keystone Resort, Colorado: ”Downstream Modulators of PPAR Action”. April/May, 1999.

243. Endothelial derived vasoactive substances and free radicals in perinatal biology, NIH, Washington: “Estrogen receptors - current concepts”. May, 1999.

244. Directors Seminar, NIH, Washington: ”New dimensions in nuclear receptor signaling”. May, 1999.

245. EMBO Workshop, Steroid and Nuclear receptors, Villefranche, France: “Biology and mechanism of action of estrogen receptor ”. May, 1999.

246. Int. Conference on Diet and Prevention of Cancer, Tampere, Finland: “ER - an antioxidant receptor”. May/June, 1999.

247. Gordon Conference on Mammary Gland Biology, Hennecker, New Hampshire, USA, June 1999: ”ER: New excitement”. June, 1999.

248. XIIIth International Symposium on Gnotobiology, Djurönäset, Stockholm: Steroid hormones, nutrients, nuclear receptors and coactivators – important players in control of gene expression”. June, 1999.

31


249. Nobelsymposium 113, “Estrogens and women’s health – benefit or threat?”, Karlskoga, Sweden: “ER - a new paradigm in estrogen mechanism of action”. June/July, 1999.

250. Gordon Conference Research on Hormonal Carcinogenesis, New Hampshire, USA: “Estrogen receptor : structure and function”. August, 1999.

251. 11th International Conference on Cytochrome P450, Sendai, Japan: “Nuclear receptors – and update”. August, 1999.

252. Japanese Endocrine Disruptor Research Project, Tokyo, Japan: “ER - a new dimension in understanding of estrogen action”. September, 1999.

253. 6th International Congress on Hormones and Cancer, Jerusalem, Israel: “Recent advances in our understanding of the respective biological roles of estrogen receptor and estrogen receptor ”. September, 1999.

254. Neuronal and cognitive effects of oestrogens, London, England: “New horizons in estrogen mechanisms of action – estrogen receptor ”. September, 1999.

255. ECCO10 – the European Cancer Conference, Vienna, Austria: “Estrogen receptor beta – new developments”. September, 1999.

256. International workshop: Estrogens and Male Reproduction (EMR), Isola Capo Rizzuto, Crotone, Italy: “The role or estrogen receptor beta in male reproductive tissues”. September, 1999.

257. The 9th International Menopause Society World Congress on the Menopause, Yokohama, Japan: “ER - new dimensions in estrogen mechanism of action”. October, 1999.

258. Svenska Mässan, “From Idea to Blockbuster”, Gothenburg: “Novel nuclear receptors – a paradigm shift in drug development”. November, 1999.

259. SERMs: Implications for Prevention and Treatment of Breast Cancer, Philadelphia, USA: “ER: More Surprises”. November, 1999.

260. National Institutes of Health, Menopause and Women’s Health – a Global Approach, USA: “Physiological role of estrogen and estrogen receptors". November, 1999.

261. 2nd Biennial International Meeting Flemish Gyneacological Oncology Group, Brussels, Belgium: “New insights in ER research – The ER “. December, 1999.

262. International Symposium on Induction of Drug Metabolism From Molecular Mechanisms to Drug Approval, Stockholm, Sweden: “Recent advances in our understanding of receptor mediated induction of drug-metabolizing enzymes”. December, 1999.

263. The Second International Symposium on: The Molecular Biology of Breast Cancer, Lillehammer, Norway: “Estrogen receptors and in the rodent mammary gland”. March, 2000.

264. Congres Infertiliteit, gynaecologie en obstetrie anno 2000, Rotterdam, Netherlands: “Estrogen receptors; modulation and clinical practise". March, 2000.

265. Estrogens: From research to clinical practice (Hormone-dependent cancers and menopause), Montpellier, France: “ER - a paradigm shift in our understanding estrogen action”. March, 2000.

32


266. Keystone Symposia, Nuclear Receptors 2000, Steamboat Springs, Colorado, USA: “ER- Surprises never end”. March, 2000.

267. Sixth International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy, Stockholm, Sweden: “Roles of estrogen receptor in the CNS”. April, 2000.

268. Nuclear Receptors in the Brain, Potential targets for therapeutic agents, Oegstgeest, The Netherlands: Keynote lecture: “News and views on nuclear receptors”. April, 2000.

269. 4th Annual Frontiers in Estrogen Action, Palm Beach, Florida, USA: Coorganizer and cochairman. April, 2000.

270. 27th European Symposium on Calcified Tissues, Tampere, Finland: Keynotelecture: “Biological role of ER and ER“. May, 2000.

271. Estrogens: bone and vascular targets, Paris, France: “Estrogen receptor - a paradigm shift in understanding estrogen action”. May, 2000.

272. SFT seminar on Phytoestrogens, Stockholm, Sweden: “A paradigm shift in our understanding of estrogen action”. May, 2000.

273. Swiss Bone and Mineral Society, Basel, Switzerland: “ER - a new dimension in estrogen action”. May, 2000.

274. Int. Conf. on the Female Reproductive Tract, Frauenwörth, Germany: “Estrogen receptor - role in reproduction”. May, 2000.

275. Annual Meeting of the German Endocrine Society, München, Germany: “New dimensions in estrogen receptors’ mechanisms of action”. June, 2000.

276. 6th Reisenburg International Symposium, Thyroid 2000: From bench to bedside, from gene to patient, Reisenburg, Germany: “Nuclear receptors in control of lipid homeostasis”. June, 2000.

277. ASPET, Burroughs Wellcome Fund Lecture, Boston, USA: “Estrogen receptor - A paradigm shift in understanding estrogen action”. June, 2000.

278. 7th Nordic Nutrition Congress, Mariehamn, Åland: “ Nutrients in control of gene regulation”. June, 2000.

279. Hormone-dependent Cancers and Nuclear Receptors, Saitama, Japan: “Role of estrogen receptor and in steroid hormone-dependent tissues and cancers”. June, 2000.

280. International Meeting on Women’s Health and Menopause, NIH, Washington D.C., USA: “Physiological Role of Estrogen and Estrogen Receptors”. July, 2000.

281. 14th Ecdysone Workshop, Rapperswil, Switzerland: “On a paradigm shift in our understanding of estrogen mechanism of action: Discovery of estrogen receptor “. July, 2000.

282. VIth International Conference on Hormones, Brain and Behavior & The Society for Behavioral Neuroendocrinology, Madrid, Spain: Keynote Lecture “Recent developments in our understanding of estrogen action: Estrogen Receptor “. August, 2000.

33


283. FEBS Advanced Study Institute, International Summer School on New dimensions in the regulation of gene expression, Spetses, Greece: “Novel mechanisms in estrogen signalling” and “Nuclear receptor regulated lipid homeostasis”. August, 2000.

284. Third Annual Symposium on “Functional genomics – the human touch”, Gothenburg, Sweden: “Potential of genomics for diagnosis and drug development – the example of the steroid receptor superfamily”. August, 2000.

285. EUROTOX 2000, XXXVIII European Congress of Toxicology, London: “The role of the ER in oestrogen mediated carcinogenesis”. September, 2000.

286. A Joint International Symposium arranged by the Center for Biotechnology (CBT), Karolinska Institutet and EUROSTERONE in collaboration with the Summer University of Southern Stockholm, “Nuclear Receptors in Health and Disease”, Huddinge, Sweden: “Estrogen receptor - A paradigm shift in understanding estrogen action”. September, 2000.

287. Pannon Symposium, Tissue-selective estrogen action: from basic science to the clinical practice, Pécs, Hungary: Keynote lecture “Estrogen receptor-: A paradigm shift in understanding estrogen action”. September, 2000.

288. BioTech Forum, Älvsjömässan, Stockholm, Sweden: “Rational drug design based on steroid hormones and their receptors and the interaction between academic research and KaroBio AB”. October, 2000.

289. Cinquièmes Journées Européennes de la Sociéte Francaise de Gynécologie, Paris, France: “Estrogen receptors”. October, 2000.

290. Cardiovascular Disease and Hormone Replacement Therapy, IMS Workshop Royal Society of Medicine, London, U.K.: “Estrogen receptors”. October, 2000.

291. E.hormone 2000 – the cutting edge of endocrine disrupter research, Tulane University, New Orleans, U.S.A.: “Estrogen receptor - a paradigm shift in our view on estrogen signaling and endocrine disruption”. October, 2000.

292. Keynote Lecture at Hormones and cancer 2000 and Aromatase 2000 and the 3rd generation, Port Douglas, Queensland, Australia: “Estrogen receptor – a paradigm shift in understanding estrogen action”. November, 2000.

293. Keynote Lecture at Garvan Symposium “Estrogens & Womens Health”, Sydney, Australia: “Mechanisms of estrogen action: the role of ERbeta”. November, 2000.

294. Keynote Lecture at Steroid receptor and cell signaling, Cincinnati, University of Cincinnati, USA: “Estrogen receptors and control of proliferation”. November, 2000.

295. European Medal Lecture. 191st Meeting of the Society for Endocrinology, London, U.K.: “Estrogen receptor - a paradigm shift in understanding estrogen action”. November, 2000.

296. 23rd Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA: “ER and ER : “The Yin-Yang principle of estrogen action”. December, 2000.

297. 1st Meeting of the Network “Environmental Estrogens and their Effects in Health and Disease”, Athens, Greece: “The mechanism of action of estrogens – The role of ER“. January, 2001.

34


298. Mayo Clinic, Rochester, USA: “Estrogen Receptor Beta – a Breakthrough in Understanding Estrogen Signaling”. February, 2001.

299. II International Symposium of the Portuguese Menopause Society, Menopause: Hormones and Cancer, Lisbon, Portugal: “Estrogen receptors and Breast Cancer”. March, 2001.

300. Disorders of the Prostate. Advances in Basic Mechanisms and the Implications for Clinical Management, Castres, France: “Oestrogen receptor beta knock out leads to hyperplasia in the ventral prostate”. March, 2001.

301. Experimental Biology 2001, The American Association of Immunologists, Orlando, Florida, USA: “Molecular aspects of estrogen receptors alpha and beta”. March/April, 2001.

302. 5th Annual Frontiers in Estrogen Action, County Clare, Ireland: “ER biology: New Frontiers”. April, 2001.

303. EMBO Workshop on Nuclear Receptor Structure and Function, Erice, Italy: “Novel aspects on estrogen signaling”. May, 2001.

304. 4th International Symposium on Women’s Health and Menopause, Washington DC, USA: “Estrogen signaling – New Paradigms”. May, 2001.

305. Eukaryotic Transcription: From mechanism to function, Turku, Finland: “Estrogen Receptors”. June, 2001.

306. Neuroendocrine Workshop on Hormones, Mood and Behavior, Breckenridge, Colorado, USA: “Estrogen receptor ”. June, 2001.

307. FASEB Summer Research Conference Program “Steroids and Bone”, Whitefish, Montana, USA: “ER-ER interplay in estrogen action”. June, 2001.

308. A Eurosterone Thematic Conference: Steroid signalling: New Frontiers, Edinburgh, Scotland: “New Frontiers in estrogen signalling”. June, 2001.

309. XIth International Congress on Genes, Gene Families and Isozymes; Stockholm, Sweden: “The nuclear receptor super gene family – developments and highlights”. June/July, 2001.

310. 17th Annual meeting of the European Society of Human Reproduction and Embryology, Lausanne, Switzerland: “Transgenic models in reproductive research”. July, 2001.

311. Bone and Tooth Society, Annual Meeting, Warwick, UK: “Regulation of transcription by different estrogen receptors”. July, 2001.

312. 15th Annual Symposium on The Long-Term Effects of Estrogen Deprivation, Bermuda: “Phenotypes of ER knockout mice”. July, 2001.

313. 7th International Summer School Behavioral Neurogenetics, Lake Erken, Norrtälje, Sweden: “A tale of two estrogen receptors”. July, 2001.

314. IMCB, Singapore: “New paradigms in estrogen signalling – estrogen receptor beta” and “LXRalfa and LXRbeta – two novel and important regulators of cholesterol homeostasis”. July, 2001.

35


315. Nuclear Receptors – Recent Developments, Oslo, Norway: “New paradigms in estrogen signalling”. August, 2001.

316. XXIII Congress of the European Society of Cardiology together with the 36th Annual General Meeting of the Association for European Paediatric Cardiology, Stockholm: “Update on estrogen receptors”. September, 2001.

317. The Charles Brenton Huggins Memorial Symposium, Chicago, USA: “ER-beta: A receptor with many faces”. September, 2001.

318. XXVIth European Symposium on Hormones and Cell Regulation, Mont Ste Odile: “On the role of estrogen receptor beta in reproduction” and “LXRs”. September, 2001.

319. Benzon Symposium No 48: Drug Metabolism Regulation and Importance, Copenhagen: “Molecular mechanisms of CYP induction”. September, 2001.

320. Medicon Valley BioConference 2001, Copenhagen, Denmark: “Nuclear receptors as target for drug development – A scientifically and commercially hot area that may serve as a role model for a new paradigm in academic research”. September, 2001.

321. 8th ICEM, Shizuoka, Japan: Plenary lecture “Nuclear receptor – environment interactions”. October, 2001.

322. Science in Japan Forum, Stockholm: “Recent advances in understanding nuclear receptors”. October, 2001.

323. 3rd Biennial International Meeting of the Flemish Gynaecological Oncology Group, Endocrine treatment and prevention of breast and gynaecological cancers, Brussels, Belgium: “The latest on ER beta in gynaecological and breast cancers”. November, 2001.

324. 2001 Workshop on Genomic vs non-genomic steroid action: Encountered or unified views, Madrid, Spain: “The nuclear-receptor interacting proteins”. December, 2001.

325. First International Nuclear Receptor Meeting in Japan, Kyoto, Japan: “An update on the biology of estrogen receptor beta”. March, 2002.

326. 2nd Annual Lectureship inWomen’s Health Research “From estrogen receptors to management of menopause”, Washington, USA: “Estrogen receptor – A multifaceted player”. March, 2002.

327. Lecture at Chinese Academy of Medical Sciences, Beijing, China: “Recent advances in our understanding of estrogen signalling pathways”. April, 2002.

328. 6th Annual Frontiers in Estrogen Action, Amelia Island, Florida: “Update on the biology of ER”. April, 2002.

329. 7th Congress of the European Society of Contraception, Genova, Italy: “Steroid receptors”. April, 2002.

330. Keystone meeting on Nuclear Receptor Superfamily, Snowbird, Utah, USA: “On the role of ERbeta in the CNS”. April, 2002.

331. Swiss National Research Programme (NRP) 50 “Endocrine Disruptors”, Zürich, Switzerland: “Steroid receptors and transcription mechanisms: action of endocrine disruptors”. April, 2002.

36


332. Hormones and Genome: Basic research towards improvement of diagnostic and therapeutic medicine, Blaubeuren/Ulm, Germany: “New paradigms in estrogen signaling – ER as the Deus ex machina”. May, 2002.

333. Fourth Annual Symposium on Developmental & Molecular Toxicology, Development and Genetic Aspects of Breast Cancer, Madison, Wisconsin, USA: “Estrogen signaling – a matter of thesis and antithesis”. June, 2002.

334. 10th World Congress on the Menopause, Plenary lecture, Berlin, Germany: “Estrogen receptor – a multifacetted player”. June, 2002.

335. XIVth World Congress of Pharmacology, Plenary lecture, San Fransisco, USA: “Estrogen receptors”. July, 2002.

336. Conférence du Centre de recherche, Quebec, Canada: “Estrogen receptor - an important and multifacetted player in estrogen signaling”. July, 2002.

337. National Cancer Centre, Tokyo, Japan: “Novel aspects on estrogen signaling and hormone dependent cancer”. July, 2002.

338. 14th International Symposium on Microsomes and Drug Oxidations (MDO 2002), Sapporo, Japan: “Crosstalk between PPAR and LXR: Two major regulators of lipid metabolism”. July, 2002.

339. Summer School/Bregenz 2002, “From genes via endocrine models to patients”, Bregenz, Austria: “ER , ER and more” and “ED interactions with ER and ER”. July, 2002.

340. International Summer School on Neurotrophin and Nuclear Receptors: From Molecules to Behaviour, Lake Erken, Norrtälje, Sweden: “Estrogen receptors: alpha and beta”. August, 2002.

341. Nuclear Receptors 2002 - A Joint International Symposium arranged by the Center for Biotechnology (CBT), Karolinska Institutet in collaboration with the Summer University of Southern Stockholm, Huddinge, Sweden: “ERbeta as a regulator of cellular proliferation”. August, 2002.

342. The 5th International Congress of Neuroendocrinology, Bristol, U.K.: “Genomic and non-genomic actions of steroids”. August/September, 2002.

343. Nuclear receptors and disease, Göteborg, Sweden: “Sterol homeostasis controlled by nuclear receptors”. September, 2002.

344. 30th Conference of the European Teratology Society in conjunction with the symposium Adverse effects of endocrine disruptors, Hannover, Germany: “Mechanisms of endocrine signaling”. September, 2002.

345. 26th Congress of the Société Internationale d’Urologie, Stockholm, Sweden: State-of-the-Art-Lecture: “The role of estrogen-receptor beta in control of prostate growth”. September, 2002.

346. ENEA 2002 Münich, 10th Meeting of the European Neuroendocrine Association, Münich, Germany: “Estrogen receptors”. September, 2002.

347. European Respiratory Society, Annual Congress 2002, Stockholm, Sweden: “Glucocorticoid receptors and cell signalling (overview talk)”. September, 2002.

37


348. Molecular mechanisms as targets in prostatic diseases, Liverpool, UK: “The role and function of ER-beta in the development of prostate cancer”. September, 2002.

349. 2nd European Congress of Andrology, Malmö, Sweden: “A novel endocrine pathway in the prostate, ER, AR, 5 -androstane-3, 17-diol, and CYP7B1, regulates prostate growth”. September, 2002.

350. International Society for the Study of Women’s Sexual Health, Annual Meeting 2002, Vancouver, Canada: State of the Art Lecture, “New paradigms in understanding estrogen signaling”. October, 2002.

351. Tianjin TEDA Watson Biopark Development Conference, Tianjin, China: “Recent advances in our understanding of nuclear receptor action”. October, 2002.

352. e.hormone 2002, New Orleans, USA: “Environmental signals: Multiple receptors & multiple inputs”. October, 2002.

353. Women’s Health Special Interest Group (WHSIG), NIH; Washington, USA: “Estrogen receptors – from molecular biology ot therapeutics”. November, 2002.

354. Burroughs Wellcome Fund Visiting Professorship In the Basic Medical Sciences, University of Texas Medical Brand School of Medicine, Houston, Texas, USA: “A new paradigm in estrogen signaling provided by the dynamic interplay between ERalpha and ERbeta”. November, 2002.

355. Biomedicum Helsinki Seminars: Frontiers in Medicine, Helsinki, Finland: “Nuclear receptors and regulation of cholesterol homeostasis”. November, 2002.

356. Fourth Amazon Project Conference, Innaovative Strategies and Perpectives in Cancer Care, Palermo, Italy: “The novel estrogen receptor beta – possible implications for breast cancer”. November, 2002.

357. British Pharmacological Society Wintermeeting, Nuclear receptors: targets for new therapies, Brighton, U.K.: “Oestrogen receptors”. January, 2003.

358. Symposium Regulation of cell signalling by estrogens and phytoestrogens, McDowell Lecture in Physiology, London, U.K.: “Estrogens – how do they work?”. January, 2003.

359. Distinguished Guest for 2003 in the Molecular and Cellular Biology Department at Baylor College of Medicine, Houston, Texas, U.S.A.: “A new look on estrogen signaling”. February, 2003.

360. Ernst Schering Research Foundation, Workshop 46, New molecular mechanisms of estrogen action and their impact on future perspectives in estrogen therapy, Berlin, Germany: “Novel functions of ER as revealed by studies of phenotypes of ER K.O.-mice”. March, 2003.

361. International Group on Insulin Secretion, Novel Factors in the Regulation of -cell function, St. Jean-Cap-Ferrat: Keynote Lecture, “Frontiers in nuclear receptors research”. March, 2003.

362. On Target 2010: The Future of Medicines, Stockholm, Sweden: “The academic research perspective”. April, 2003.

363. Chairman at the 7th Annual Frontiers in Estrogen Action, The Homestead, Hot Springs, Virginia. April, 2003.

38


364. 6th European Congress of Endocrinology, Lyon, France: Plenary Lecture, “Role of estrogen receptors: lessons from knock-out mice”. April, 2003.

365. Calcified Tissue International, Rome, Italy: Plenary Lecture, “Modulation of estrogen action by ER isoforms”. May, 2003.

366. Novel approaches to treatment in hormone-sensitive breast cancer, London, U.K.: “Elucidation of ER function in breast cancer”. May, 2003.

367. Utrecht Graduate School of Developmental Biology, Utrecht, The Netherlands: “New paradigms in estrogen signaling”. June, 2003.

368. 2nd Dutch Endo-Neuro-Psycho meeting, Doorwerth, The Netherlands: Marius Tausk Lecture, “New paradigms in estrogen signaling”. June, 2003.

369. EMBO Conference, Biology of Nuclear Receptors, Villefranche-sur-Mer (Nice), France: “Antiproliferative actions of estrogen receptor ”. June, 2003.

370. Special Symposium on estrogen receptors, Los Angeles, USA: “Estrogen receptor-beta – A paradigm shift in understanding estrogen signaling”. June, 2003.

371. Allosteric Mechanisms of Signal Transduction, Paris, France: “Estrogen signaling – importance of conformational changes in estrogen receptor action”. June, 2003.

372. European Code against cancer, Clinical Cancer Research in Europe, Milan, Italy: “Oestrogen signaling and cancer”. June, 2003.

373. Fourth International Symposium on Hormonal Carcinogenesis, Valencia, Spain: “A novel mechanism for control of prostate growth”. June, 2003.

374. Special FEBS 2003 Meeting on Signal Transduction; Signal transduction: from membrane to gene expression, from structure to disease, Brussels, Belgium: Datta Lecture “Update on estrogen signaling”. July, 2003.

375. 19th Ernst Klenk Symposium, Transcriptional and other regulatory mechanisms of lipid metabolism, Cologne, Germany: “Some phenotypes of LXR KO mice”. July, 2003.

376. HLSC 2nd event, Hormones and Genome, Molecular Mechanisms in Metabolic Diseases: Obesity, Diabetes Type 2, Lipid disorders and Atherosclerosis – Basic Science towards Clinical Application, Ulm, Germany: “Some phenotypes of LXR KO mice”. July, 2003.

377. Summer School on Endocrinology, Bregenz, Austria: “Estrogen receptors and metabolic syndrome”. July, 2003.

378. Nobel Conference No 40, Transcriptional control of lipid homeostasis, Stockholm, Sweden: “LXR and control of lipid homeostasis”. August, 2003.

379. FEBS Advanced Study Institute, International Summer School, From transcription to physiology: Regulation of gene expression and protein function in an integrated context, Spetses, Greece: “Mechanisms of estrogen action” and “Insight into the biology of estrogen and Liver X receptors by studying knock-out mice”. September, 2003.

380. 8th Nottingham International Breast Cancer Conference, Nottingham, U.K.: “Development and an overview of ER“. September, 2003.

381. Lecture at the University of Mainz, Institute of Toxicology, Mainz, Germany: “New views on estrogen signaling”. September, 2003.

39


382. Rudbeck seminars, Uppsala University: “New understanding of estrogen action”. September, 2003.

383. The Endocrine Society: The Role of Nuclear Receptors in Cardiovascular Disease, San Diego: “Estrogens and the Immune System: Novel Lessons from ERalfa and ERbeta KO Mice”. October, 2003.

384. The 2nd International Symposium of Gender Related Medicine at Centre of Gender Related Medicine, Karolinska Institutet, Stockholm, Sweden: “New paradigms of estrogen signalling – genderaspects”. October, 2003.

385. Maturitas Master Class, Lisbon, Portugal: “Steroid receptors” and “Specific alpha and beta ER-ligands”. October, 2003.

386. International School of Medical Science, 117th Advanced Course on Signal Transduction and Communication in Cancer Cells, Erice, Italy: “Estrogen Receptor Beta in Development and Cancer”. October, 2003.

387. Eleventh Annual Nuclear Receptor Symposium, Nuclear Receptors: Discovery, Biology, and Therapy, Stevenage, U.K.: “Novel views on estrogen signaling”. October, 2003.

388. 13th Annual Meeting of the Dutch Society for Calcium and Bone Metabolism, Zeist, The Netherlands: “Estrogen signaling – a case of yin and yang”. October, 2003.

389. The 6th U.S.- Taiwan Neuroscience Symposium, Estrogen actions in the brain, New Orleans, USA: “ERbeta in the nervous system”. November, 2003.

390. Bengt E Gustafsson Symposium, Microbial Ecology in Health & Disease, Born germfree – microbial dependent, Stockholm: “Metabolism”. November, 2003.

391. Jensen Symposium, Nuclear Receptors and Endocrine Disorders, Cincinnati, USA: “Estrogens and diseases of brain and the immune system”. December, 2003.

392. Boosting Innovation from Research to Market, Bryssel, Belgium: “Academy-industry interactions at the Novum Campus in Stockholm”. December, 2003.

393. The Biotechnology, the Capital and the Brain – The Mixing Chemistry of Bioeconomy, Beijing, China: “Nuclear Receptors – From Academia to Commercial Application”. December, 2003.

394. Rui Jin Hospital, Shanghai, China: “Yin-yang of estrogen signaling”. December, 2003.

395. Workshop Nuclear Receptors, Leiden, Netherlands: “Estrogen receptor-beta – a multifunctional transcription factor”. January, 2004.

396. Updates in Infertility Treatment, Marco Island, Florida, USA: “Novel functions of estrogen receptor beta”. January, 2004.

397. A. I. Virtanen Institute Research Seminars, Kuopio, Finland: “A new look upon estrogen signaling”. January, 2004.

398. Keystone Symposia on Nuclear Receptors: Orphan Brothers, Keystone Resort, Colorado: “New roles of estrogen receptor ”. February, 2004.

399. Umeå University: “Estrogen signaling – an area of rapid development and relevance”. March, 2004.

40


400. ERPM 2004, Stéroïdes sexuels: le point sur l’action des estrogènes et des progestatifs. Montpellier, France: “Effects of ER on the CNS”. March/April 2004.

401. 55. Mosbacher Kolloquium: How nutrients influence gene activity, Mosbach, Baden, Germany: “On the role of estrogen receptors and liver X receptors in lipid metabolism”. April, 2004.

402. 15th Symposium on Growth Hormone and Endocrinology, Malta: “Estrogen receptor beta regulates epithelial cell differentiation in the mouse ventral prostate”. April, 2004.

403. European Atherosclerosis Society, 74th EAS Congress, Seville, Spain: “Estrogen signaling and the cardiovascular system – some new angles”. April, 2004.

404. 5th International Symposium on Women’s Health and Menopause, Florence, Italy: “ER - A multifunctional regulator of women’s health”. April, 2004.

405. Hormones and the Genome, HLSC 3rd event, Endocrine malignancies and autoimmunity, Molecular biological events and targets for clinical application, Ulm, Germany: “Estrogen signaling and the immune system – new excitements”. April, 2004.

406. Nuclear receptors, transcription, and cancer symposium, University of Virginia, Virginia, USA: “A new look at estrogen signaling”. May, 2004.

407. Eli Lilly, Indianapolis, Illinois, USA: “Recent excitements in estrogen signaling”. June, 2004.

408. Breast Cancer Meeting, New Orleans, USA: “New vistas in estrogen signaling”. June, 2004.

409. Environmental and Endocrine Signaling, A Satellite Symposium preceding the annual Society of Endocrinology Meeting, New Orleans, USA: “Nuclear receptors as signal sensors”. June, 2004.

410. Workshop “Food safety and quality: state of research in the Southern Mediterranean Agronomic Studies”, Bari, Italy: “Projet CE: CASCADE”. July, 2004.

411. MDO 2004, 15th International Symposium on Microsomes and Drug Oxidations: Chemical biology in the postgenomic era; new approaches and applications, Mainz, Germany: “Role of P450 in steroid hormone action”. July, 2004.

412. Seventh International Symposium on Neurobiology and Neuroendocrinology of Aging, Bregenz, Austria: “The role of the estrogen receptor in neuroprotection”. July, 2004.

413. Summer School on Endocrinology, Nuclear Receptors, Endocrine Disruptors and Metabolic Effects, Bregenz, Austria: “ER and immunology”. July, 2004.

414. 37th Annual Meeting of the Society for the study of reproduction, Vancouver, British Columbia, Canada: “Targeting cancers by estrogens and its analogs”. August, 2004.

415. XVIII World Congress International Society for Heart Research, Brisbane, Australia: Estrogen derivatives in cardiovascular disease-old questions, new answers; “New paradigms in estrogen signaling with particular reference to cardiovascular function”. August, 2004.

416. XVIIIth International Symposium on Medicinal Chemistry, Copenhagen, Denmark: “Recent excitements in drug development based on novel insights in estrogen signaling”. August, 2004.

41


417. UT Forum 2004 in Sweden, Medical and Life Sciences, “Molecular Medicine and Its Recent Advances”, Stockholm, Sweden: “New vistas in estrogen signaling: Therapeutical implications”. August, 2004.

418. ESPE 18th Summer School 2004, “Estrogen receptor”, Ramsach, Switzerland: “Estrogen receptor”. September, 2004.

419. 55th Annual Meeting of the European Association for Animal Production, Bled, Slovenien: “Estrogen signaling in the mammary gland”. September, 2004.

420. 43rd Annual Meeting of the European Society for Pediatric Endocrinology, Basel, Switzerland: “New paradigms in estrogen signaling and their clinical implications”. September, 2004.

421. CASCADE Summer School on Nuclear Receptors, ENS Lyon, Lyon, France: “LXR and ER signaling”. September, 2004.

422. Inaugural COST 926 Conf. Eur. Workshop on Cellular Responses to bioactive plant compounds – implications for human health, Budapest, Hungary: Keynote lecture “Estrogen signaling and cancer prevention”. September/October, 2004.

423. Nuclear Receptors 2004 - An International Symposium arranged by the Center for Biotechnology (CBT), Karolinska Institutet, Huddinge, Sweden: “Estrogen signaling in new light”. October, 2004.

424. Annual Bristol-Myers Squibb/Mead Johnson Nutrition Award Symposium, New York, USA: “New paradigms in estrogen signalling”. October, 2004.

425. China TEDA Bioforum, Tjianjin, China: “Nuclear Receptors, A rapidly developing field”. October, 2004.

426. e.hormone 2004, Tulane University, New Orleans, USA: “New surprises in estrogen signaling”. October, 2004.

427. Nuclear Receptors and Genomic Medicine, Saitama Medical School, Saitama, Japan: “A new look at estrogen signaling”. November, 2004.

428. National Cancer Center Research Institute, Tokyo, Japan: “ER and cancer”. November, 2004.

429. Tokyo University, Inst. of Molecular and Cellular Biosciences, Japan: “Novel concepts in estrogen signaling open up new therapeutical possibilities in many areas”. November, 2004.

430. Biomedicum Helsinki, Helsinki, Finland: “New paradigms in estrogen signaling open up novel pharmaceutical approaches for several diseases”.

431. DG RTD Workshop: Mechanisms of organ specific ageing, Brussels, Belgium: “Steroids and ageing”. December, 2004.

432. China University of Science & Technology, Hefei, China: “New excitements in estrogen signalling”. December, 2004.

433. Institute of Neuroscience, Chinese Academy of Sciences, Shanghai, China: “Estrogen signalling in the CNS”. December, 2004.

42


434. Cascade 1st Annual Meeting, Chemical Contaminants in Food: Proposals for Scientific Research, Orvieto, Italy: “Nuclear receptors – an overview”. January, 2005.

435. Enhanced International Collaboration in the Field of Endocrine Disrupters: How to do it in practice? Workshop Organised by the European Commission’s Research Directorate-General, Brussels, Belgium: “Integration of international organisations in CASCADE network of excellence: Chemicals as contaminants in the food chain: a network of excellence for research, risk assessment, education and information”. January, 2005.

436. Keystone symposia on Hormonal Regulation of Tumorgenesis, Monterey, California, USA, February 2005: “Antiproliferative actions of ER”. February, 2005.

437. Keynote Lecture at Symposium in the honor of Dr. Paul van der Saag, Utrecht, The Netherlands: “Nuclear receptors during two centuries”. March, 2005.

438. 2nd Ernst Knobil Memorial Lecture, San Diego, USA: “Estrogen receptor beta – a multifunctional regulator”. April, 2005.

439. 8th Frontiers in Nuclear Receptor, Phoenix, Arizona, USA: “Estrogen signaling – New mechanisms”. April, 2005.

440. 40th Anniversary of the IARC, Lyon, France: “Estrogen receptor as novel target for antiproliferative drugs”. May, 2005.

441. The fifth annual meeting of the Network for functional studies in mice, Stockholm, Sweden: “Lessons learnt from ERbeta and LXRbeta KO mice”. May, 2005.

442. 62nd KSBMB Annual Meeting in 2005 – From mechanism to functions, Seoul, South Korea: Keynote Lecture “Estrogen receptor - a novel tumor suppressor gene?”. May, 2005.

443. Nobel minisymposium “Sex differences in the human brain, their mechanisms and implications”, Stockholm, Sweden: “ERbeta and CNS function”. May, 2005.

444. 6th Puberty Conference, Evian, France: “Precocious puberty and early ovarian failure in CYP7B1 knockout mice”. May, 2005.

445. ENDO 2005, San Diego, USA: “Estrogen receptor beta”. June, 2005.

446. Engebretson symposium on drug discovery and development in cancer experimental therapeutics, Minnesota, USA: Keynote lecture “Recent excitements in drug development based on novel insights in estrogen signalling”. June, 2005.

447. 8th Int. Congress of Andrology and 22nd Annual Meeting of Korean Andrological Society, Men’s health – nature and nurture, Seoul, Korea: “Estrogen receptor : an antiproliferative principle in the prostate”. June, 2005.

448. The Third International Symposium on the Molecular Biology of Breast Cancer, Molde, Norway: “ERin normal and malignant breast”. June, 2005.

449. CASCADE Open Forum, The chemical pollutants in our food, Visby, Sweden: “Hormone-disrupting chemicals – what are they?”. July, 2005.

450. Descartes Prize Nominee Meeting, Brussels: “Pathfinder – a Euorpean network for research on nuclear receptors”. July, 2005.

43


451. Hormone Action in Development & Cancer, Gordon Research Conference, Mount Holyoke, South Hadley, USA,: “Antiproliferative actions of Erbeta – mechanisms and possible pharmaceutical applications”. July, 2005.

452. Eli Lilly, Indianapolis, July 2005: “ER - a multifunctional regulator”. July, 2005.

453. Inje University, Busan, Korea, July 2005,1. “The liver X receptor”2. “Recent advances in understanding estrogen action”3. “Karolinska Institutet and Biomedical Science Park in Sweden”

454. Int. Workshop on Physical Sciences at the Microscale and First IAAC meeting of HFNL, Hefei and Huang shan, China: “Mechanisms of action of female sex hormones”. August, 2005.

455. 46th International Conference on the Bioscience of Lipids, Ajaccio, Corsica: “The role of LXR in the liver, adipocytes and nervous system”. September, 2005.

456. Center for Molecular Medicine, University of Cologne, Cologne, Germany: “Estrogen receptor beta – a new paradigm in estrogen signaling”. September, 2005.

457. EMBO Conference, Nuclear Receptor: From Chromatin to Disease, Lake Garda, Italy: “ERbeta – an antiproliferative principle”. September/October, 2005.

458. 1 Simpósio Mulher Sempre Mulher, Hormones and Breast Estrogen Receptor Beta and SERM’s, Lisbon, Portugal: “Estrogen receptor beta in breast cancer”. October, 2005.

459. Int. symp. Endocrine disrupters – Occurrence in the bioenvironment and possible effects in animals and humans, Oslo, Norway: “New surprises in estrogen signalling”. October, 2005.

460. Fourth Annual AACR Int. Conf., Frontiers in Cancer Prevention Research, Baltimore, USA: “Estrogen receptors and breast cancer”. October/November, 2005.

461. China TEDA Bioforum, Advances in Life Sciences, Tianjin, China: “Estrogen receptor in breast cancer”. November, 2005.

462. The MTC Annual Talks 2005, Nobel Forum, KI, Stockholm, Sweden: “On the role of estrogen receptor in the immune system”. November, 2005.

463. University of Kentucky, Lexington, USA: “A new look on estrogen signaling: The role of estrogen receptor “. January, 2006,

464. Yale University School of Medicine, Pharmacology Seminar Series, New York, USA: “A new look at estrogen signaling”. January, 2006.

465. University of Milan, EWA – Estrogens and Women Aging, Milano, Italy: “Erbeta and menopause”. January, 2006.

466. The 1st World Congress on Gender-Specific Medicine, “Men, Women, and Medicine: A New View of the Biology of Sex/Gender Differences and Aging”, Berlin, Germany: “Estrogen receptors in the brain”. February, 2006.

467. European Society for Clinical Investigation, 40th Annual Scientific Meeting, Prague, Czech Republic: Plenary lecture, “Clinical use of estrogen receptor beta”. March, 2006.

44


468. Keystone Symposia, Nuclear Receptors: Orphan Brothers, Banff, Alberta, Canada: “Biology of estrogen receptor - New insights”. March, 2006.

469. CASCADE 2nd Annual Meeting, St Malo, France: “CASCADE – past and future”. March, 2006.

470. EUROPT(R)ODE VIII, Tübingen, Germany: "Nuclear receptor signaling – a gold mine for development/application of novel techniques for studies on molecular interactions“. April, 2006.

471. 9th Frontiers in Nuclear Receptor Action, Sanibel Harbour, Ft Myers, Florida, chairman. April, 2006.

472. 41st Annual meeting of The European Association for the study of the liver, Vienna, Austria: “Liver X receptor”. April, 2006.

473. Yale University School of Medicine, OB GYN Seminar Series, New Haven, USA: “ERbeta scientific visions translate to clinical uses”. May, 2006.

474. 132nd Advanced Course on : Estrogens and Human Diseases, Erice, Italy: “Recent advances in estrogen signaling”. May, 2006.

475. 5th Gordon Research Conference on Environmental Endocrine Disruptors, Il Ciocco, Barga, Italy: “Steroid receptors, crosstalk and potential endocrine disruption”. June, 2006.

476. Symposium “Neue Erkenntnisse in der Frauenhelikunde – Gesundheit, Hormone und Soja”, Vienna, Austria: “Estrogen action – two different signaling pathways”. June, 2006.

477. 5th Int. Congress of Pathophysiology, Beijing, China: “ER - a multifunctional nuclear receptor”. June/July, 2006.

478. Second Military Medical University, Shanghai, China: “New discoveries in estrogen signaling translate into clinical medicine”. July, 2006.

479. 15th World Congress of Pharmacology, Beijing, China: “Recent advances in estrogen-signaling and new sites for pharmacological interventions”. July, 2006.

480. Academy of Military Medical Sciences (AMMS), Beijing, China: “Estrogen receptor - a new drug target”. July, 2006.

481. BioScience 2006, Glasgow, UK: “New developments in oestrogen signalling”. July, 2006.

482. Bregenz Summer School on Endocrinology: Nuclear Receptors in Health & Disease, Bregenz, Austria: Plenary Lecture: “Recent Highlights in Estrogen Signaling”. August, 2006.

483. AP ECHO, Asia-Pacific Education Center of Hematology/Oncology and Translational Medicine, Shanghai, China: “Nuclear receptors in disease”. August, 2006.

484. 12th International Congress on Hormonal Steroids and Hormones & Cancer, Athens, Greece: “Regulation of prostate growth by estrogen receptors and ”. September, 2006.

485. Nuclear Receptors 2006 - An International Symposium arranged by the Center for Biosciences, Karolinska Institutet, Huddinge, Sweden: “Role of estrogen receptor (ER) and liver X receptor (LXR) in the central nervous system”. September, 2006.

45


486. The Institute of Cancer Research, Breakthrough Breast Cancer Research Centre, London, U.K: “New paradigms in estrogen signaling rapidly translate into clinical medicine”. September, 2006.

487. 11th Annual Meeting of the European Council for Cardiovascular Research (ECCR), La Colle sur Loup, Nice, France: “The estrogen receptor and cardiovascular diseases”. September, 2006.

488. 3rd International Greek Biotechnology Forum, Athens, Greece: Honorary Lecture “Estrogen receptor beta – a new paradigm in estrogen signaling”. October, 2006.

489. Founding Symposium, International Graduate School in Molecular Medicine Ulm, Ulm, Germany: “Paradigm shifts in our understanding of estrogen signaling following the discovery of estrogen receptor beta”. October, 2006.

490. Jilin University, Department of Pathology, Changchun, China: “Novel paradigms in estrogen signaling in health and disease”. October, 2006.

491. Jilin University, Shool of Public Health, Changchun, China: “Diet and genes”. November, 2006.

492. Duodecim Symposium on Nuclear receptors in health and disease, Turku, Finland: “Novel actions of estrogen via estrogen receptor beta”. November, 2006.

493. The 10th Meeting Hirosaki International Forum of Medical Science, Hirosaki, Japan: “Novel paradigms in estrogen signaling in health and disease”. November, 2006.

494. The National Cancer Center Research Institute, Tokyo, Japan: “Estrogen receptor - a multifunctional receptor and a promising drug target”. November, 2006.

495. International Conference on Food Contaminants and Neurodevelopmental disorders, Valencia, Spain: “The role of ERalpha and beta in endocrine disruptors toxicity”. December, 2006.

496. Second meeting of the project estrogen in women ageing (EWA), Madrid, Spain: “The aromatase KO mouse – an appropriate model for menopause?”. January, 2006.

497. Keystone Symposia, Reproduction: Advances and Challenges, Santa Fe, New Mexico, USA: “Role of estrogen receptor beta in reproduction”. February, 2006.

498. Global LAM Summit, Stockholm, Sweden: “Estrogen receptor beta – a novel antiproliferative transcription factor”. February, 2007.

499. Working session on Hormonoresistance in breast cancer, Paris, France : “The estrogen receptor beta”. March, 2007.

500. Society for Endocrinology BES 2007, Birmingham, UK: “Estrogen receptors in development”. March, 2007.

501. Annual Meeting of the Swedish Society for Study of Reproduction, SSSR, Uppsala, Sweden: “Dramatic changes in understanding of estrogen action”. March, 2007.

502. Keystone Symposia, Nuclear Receptor Pathways to Metabolic Regulation, Sheraton Steamboat Resort, Steamboat Springs, Colorado, USA: “Role of estrogen signaling in the metabolic syndrome”. March, 2007.

46


503. CASCADE 3rd Annual Meeting, Helsinki, Finland: “CASCADE past and future”. April, 2007.

504. 10th Frontiers in Nuclear Receptor Action, Georgia, USA: “New roles for estrogen receptor in the developing and adult CNS”. April, 2007.

505. 9th European Congress of Endocrinology, Budapest, Hungary: “Recent developments in nuclear receptor action”. April/May, 2007.

506. Nuclear Receptors: Stucture and Function in Health and Disease, Gardone Riviera, Lake Garda, Italy: “LXRbeta – A link between beta-sitosterol and ALS-Parkinson’s dementia”. May, 2007.

507. University Hospital UZ Gasthuisberg, Leuven, Belgium: “Estrogen receptor beta – a revolutionary in estrogen signaling”. May, 2007.

508. Digestive Disease Week 2007, Washington, USA: “Estrogen signaling in the brain and gut”. May, 2007.

509. 10th Conference in Advanced Medicinal Chemistry, Thessaloniki, Greece: “A new era in devlopment of estrogenic pharmaceuticals: Alfa-estrogenic and beta-estrogenic drugs”. May, 2007.

510. 6th Dutch Endo-Neuro-Psycho Meeting, Doorwerth, the Netherlands : “Liver X Receptor beta in the CNS”. June, 2007.

511. Beijing Normal University, Beijing, China: “Estrogen receptor - a new paradigm in estrogen signaling”. July, 2007.

512. Third Military Medical University, Chongqing, China: “New aspects in estrogen signaling”. July, 2007.

513. 27th International Epilepsy Congress, Singapore: “Estrogens and depression”. July, 2007.

514. Genome Institute of Singapore: “Biology of estrogen receptor ”. July, 2007.

515. 21st Annual Therapeutic Options for Menopausal Health Conference, Pasadena, USA: “The role of estrogen signaling in the metabolic syndrome”. July, 2007.

516. Eli Lilly, Indianapolis, USA: “Estrogen Receptors and the Metabolic Syndrome”. July, 2007.

517. Tufts-New England Medical Center, Boston, USA: “Update on Estrogen Receptor Beta Signaling”. July, 2007.

518. University of Cincinatti, Cincinatti, USA: “An Update on Estrogen Signaling”. July, 2007.

519. Women’s Mental Health Symposium: A New University of Miami Initative, University of Miami, Miami, USA: “Targeting estrogen receptor beta offers new pharmaceutical opportunities – basic and applied aspects”. August, 2007.

520. Spetses Summer School on Nuclear Receptor Signalling: From Molecular Mechanisms to Integrative Physiology, Island of Spetses, Greece: “An update of ER signaling” and LXR signalling in the central nervous system”.

47


521. The Royal Swedish Academy of Sciences: Remedies from animals and plants, Stockholm, Sweden: “Medical benefit from biologically active compounds in foods. Phytosteroids”. September, 2007.

522. Charité – Universitätsmedizin Berlin, Center for Cardiovascular Research, Berlin, Germany: “Novel paradigms in estrogen signaling”. September, 2007.

523. Biomedicum Helsinki Seminar Series, Helsinki, Finland: “New paradigms in estrogen action give new pharmaceutical opportunities for women’s health”. October, 2007.

524. Brystkreft i fokus, Oslo, Norway: ”Estrogen receptor beta is antiproliferative in breast cancer”. October, 2007.

525. The Methodist Hospital Research Institute, Houston, Texas: Inaugural Diabetes and Metabolic Disease Guest Lecture: “A new paradigm for signal transduction: Estrogen receptor beta signaling”. October, 2007.

526. The thirty-eighth International Symposium of The Princess Takamatsu Cancer Research Fund, Tokyo, Japan, Current challenges in the understanding and management of colon cancer: “Estrogen receptor and colon cancer”. November, 2007.

527. Saitama Medical University, Tokyo, Japan: “LXR and the CNS – possible connections to the ALS-Parkinsonism dementia complex?”. November, 2007.

528. Menopause, andropause, anti-aging 2007, Vienna, Austria: “The different impact of various estrogenic receptors”. December, 2007.

529. Milan University, Milan, Italy: “Gender differences in targeting nuclear receptor signalling”. January, 2008.

530. Serono Symposia International Foundation, “Gene, environment, lifestyle interaction and human reproduciton, Malmö, Sweden: Keynote lecture: “Effects of perturbed estrogen signaling on reproductive function”, February, 2008.

531. Speaker at the Opening Seminar: Sweden – The Best Health Care System in the World?, Health Care Innovation Week, Swedish Health Care – Research and Innovation, Washington DC, USA. February, 2008.

532. Novel Targeted Cancer Therapies: from Cells and Mice to Patients: “Estrogen receptor beta – a potential new target for treatment of breast and prostate cancer”. Stockholm, Sweden, March, 2008.

533. The 3rd Sino-Swedish Cancer Workshop, Guangzhou and Hainan, China, “Estrogen receptors”. March, 2008.

534. China-Sweden Workshop on Cancer Treatment and Research, Tianjin, China, “Anti-proliferative action of estrogen receptor beta”. March, 2008.

535. Beijing Normal University, Beijing, China, “The new biology of estrogen signaling”. March, 2008.

536. 55th Annual Meeting of the Society for Gynecologic Investigation, San Diego, USA, “Estrogen Receptor-Beta and Reproduction”. Keynote lecture, March, 2008.

537. 55th Annual Meeting of the Society for Gynecologic Investigation, San Diego, USA, Debate “Importance of membrane steroid receptors”. For: Carol Lange, Ph.D., Univ. of

48


Minnesota, Minneapolis, MN, USA. Against: Jan-Åke Gustafsson, M.D., Ph.D. March, 2008.

538. The LAM Foundation/NHLBI Lymphangioleiomyomatosis, Int. Research Conference, Cincinnati, USA, “Antiproliferative actions of estrogen receptor beta – possible implications for LAM”. April, 2008.

539. 11th Frontiers in Nuclear Receptor Action, Savannah, Atlanta, USA, Chairman. April, 2008.

540. 7th Annual Symposium on the Environment and Hormones, e.hormone 2008, New Orleans, USA, “New Developments in Biology and Mechanisms of Action of ERbeta”. April, 2008.

541. Diabetes Research Center, Free University Brussels, Brussels, Belgium, “Estrogen signaling and the metabolic syndrome”. May, 2008.

542. Workshop on Pre-receptor steroid metabolism as target for pharmaceutical treatment, Eibsee, München, Germany, “Nuclear receptors as drug targets in metabolic diseases”. May, 2008.

543. XVI Symposium of the International Association on Gnotobiology – Joint with the XXXI Congress of the Society of Microbial Ecology and Disease, Djurönäset, Stockholm, Sweden: “Cancer and steroid receptors – state of the art”. May, 2008.

544. 33rd FEBS Congress & 11th IUBMB Conference, Biochemistry of Cell Regulation, Athens, Greece: “New developments in biology and mechanisms of action of ERbeta”. June/July, 2008.

545. Estrogen Receptor-beta – Benign Prostatic Hyperplasia, Washington, USA: “ER-beta biology – Role in Genito-urinary and reproductive systems in men”. July, 2008.

546. 7th Joint Meeting of AFERP, ASP, GA, PSE & SIF, Natural products with pharmaceutical nutraceutical, cosmetic and agrochemical interest, Athens, Greece: “Plant derived ligands of nuclear receptors and their biological effects”. August, 2008.

547. Murikka Minisymposium 2008, Cell signaling and its transcriptional readout, Murikka, Finland: “New biology of estrogen action”. August, 2008.

548. Nobel Conference on “Recent advances in understanding estrogen signaling: From molecular insights to clinical implications”, Sånga-Säby, Stockholm, Sweden: “The new biology of estrogen signaling”. September, 2008.

549. The 3rd International Congress of Gender Medicine, Stockholm, Sweden: “Estrogen signaling in the lung” and “HRT and depression”. September, 2008.

550. University of Houston, Houston, USA: “Antiproliferative actions of estrogen receptor beta”. September, 2008.

551. 13th International Congress on Hormonal Steroids and Hormones & Cancer, Quebec, Canada: “Interplay between ER and ER in estrogen signaling”. September, 2008.

552. The Thirty-ninth International Symposium of The Princess Takamatsu Cancer Research Fund, Metabolic Syndrome: Carcinogenesis and Prevention, Tokyo, Japan: “The tumor suppressor activity of estrogen receptor beta-implications for cancer prevention”. November, 2008.

49


553. National Cancer Center Research Institute, Tokyo, Japan: “New concepts in estrogen signaling”. November, 2008.

554. Round Table Meeting of the Senate Commission on Food Safety of the German Research Foundation (DFG), Phytoestrogens in food supplements and dietary foods for special medical purposes, Bonn, Germany: “Estrogen-Receptors: A short overview”. November, 2008.

555. Symposium on Sex Steroids, Gothenburg, Sweden: “Estrogen receptors”. November, 2008.

556. First Serbian Congress of Endocrinology, Belgrade, Serbia: Plenary lecture, “Estrogen receptor beta as a potential target in the treatment of prostatic cancer”. December, 2008.

557. Menopause, Andropause, Anti-Aging, Vienna, Austria, “Estrogen receptor beta as a potential target in treating aging males and females”. December, 2008.

BIBLIOGRAPHY:

Has over 1300 peer-reviewed publications. Can be sent upon request. The list below is selected.

1. J.-Å. Gustafsson and J. Sjövall: Steroids in germfree and conventional rats. VI. Identification of 15- and 21-hydroxylated C21 steroids in faeces from germfree rats. Eur. J. Biochem. 6, 236-247, 1968.

2. J.-Å. Gustafsson, R. Ryhage, J. Sjövall and R.M. Moriarty: Migrations of the trimethylsilyl group upon electron impact in steroids. J. Am. Chem. Soc. 91, 1234-1236, 1969.

3. P. Eneroth and J.-Å. Gustafsson: Steroids in newborns and infants. Identification of 20,22-dihydroxycholesterol from the monosulphate and "disulphate" fractions in human meconium. FEBS Lett. 5, 99-103, 1969.

4. I. Björkhem and J.-Å. Gustafsson: Mechanism of microbial transformation of cholesterol into coprostanol. Eur. J. Biochem. 21 428-432, 1971.

5. K. Einarsson, J.-Å. Gustafsson and Å. Stenberg: Neonatal imprinting of liver microsomal hydroxylation and reduction of steroids. J. Biol. Chem. 248, 4987-4997, 1973.

6. A. Berg and J.-Å. Gustafsson: Regulation of hydroxylation of 5-androstane-3, 17-diol in liver microsomes from male and female rats. J. Biol. Chem. 248, 6559-6567, 1973.

7. J.-Å. Gustafsson and Å. Stenberg: Irreversible androgenic programming at birth of microsomal and soluble liver enzymes active on 4-androstene-3,17-dione and 5-androstane-3,17-diol. J. Biol. Chem. 249, 711-718, 1974.

8. J.-Å. Gustafsson and Å. Stenberg: Neonatal programming of androgen responsiveness of liver of adult rats. J. Biol. Chem. 249, 719-723, 1974.

50


9. J.-Å. Gustafsson and M. Ingelman-Sundberg: Regulation and properties of a sex-specific hydroxylase system in female rat liver microsomes active on steroid sulphates. I. General characteristics. J. Biol. Chem. 249, 1940-1945, 1974.

10. J.-Å. Gustafsson and Å. Stenberg: Masculinization of rat liver enzyme activities following hypophysectomy. Endocrinology 95, 891-896, 1974.

11. J.-Å. Gustafsson and M. Ingelman-Sundberg: Regulation and substrate specificity of a steroid sulfate-specific hydroxylase system in female rat liver microsomes. J. Biol. Chem. 250, 3451-3458, 1975.

12. J.-Å. Gustafsson and Å. Pousette: Demonstration and partial characterization of cytosol receptors for testosterone. Biochemistry 14, 3094-3101, 1975.

13. J.-Å. Gustafsson, A. Larsson, P. Skett and Å. Stenberg: Influence of a novel hypophyseal factor on steroid metabolism in cultured hepatoma cells. Proc. Natl. Acad. Sci. USA 72, 4986-4990, 1975.

14. B.E. Gustafsson, K. Einarsson and J.-Å. Gustafsson: Influence of cholesterol feeding on liver microsomal metabolism of steroids and bile acids in conventional and germ-free rats. J. Biol. Chem. 250, 8496-8502, 1975.

15. J.-Å. Gustafsson and Å. Stenberg: Partial masculinization of rat liver enzyme activities following treatment with FSH. Endocrinology 96, 501-504, 1975.

16. A. Berg, J.-Å. Gustafsson, M. Ingelman-Sundberg and K. Carlström: Characterization of a cytochrome P-450-dependent steroid hydroxylase system present in Bacillus megaterium. J. Biol. Chem. 251, 2831-2838, 1976.

17. J.-Å. Gustafsson and Å. Stenberg: On the obligatory role of the hypophysis in sexual differentiation of hepatic metabolism in rats. Proc. Natl. Acad. Sci. USA 73, 1462-1465, 1976.

18. P. Eneroth, J.-Å. Gustafsson, A. Larsson, P. Skett and Å. Stenberg: Feminization of hepatic steroid metabolism in male rats with a transplanted pituitary tumor (MtT/F4). Cell 7, 413-417, 1976.

19. J.-Å. Gustafsson, M. Ingelman-Sundberg, Å. Stenberg and T. Hökfelt: Feminization of hepatic steroid metabolism in male rats following electrothermic lesion of the hypothalamus. Endocrinology 98, 922-926, 1976.

20. J.-Å. Gustafsson and Å. Stenberg: Specificity of neonatal, androgen-induced imprinting of hepatic steroid metabolism in rats. Science 191, 203-204, 1976.

21. J.-Å. Gustafsson, Å. Pousette and E. Svensson: Sex-specific occurrence of androgen receptors in rat brain. J. Biol. Chem. 251, 4047-4054, 1976.

22. P. Skett, P. Eneroth, J.-Å. Gustafsson and C. Sonnenschein: Changes in hepatic steroid metabolism in rats following transplantation of four different clones of pituitary tumor cells. Endocrinology 100, 1090-1096, 1977.

51


23. K. Fuxe, T. Hökfelt, P. Eneroth, J.-Å. Gustafsson and P. Skett: Prolactin-like immunoreactivity: localization in nerve terminals of rat hypothalamus. Science 196, 899-900, 1977.

24. M. Snochowski, Å. Pousette, P. Ekman, D. Bression, L. Andersson, B. Högberg and J.-Å. Gustafsson: Characterization and measurement of the androgen receptor in human benign prostatic hyperplasia and prostatic carcinoma. J. Clin. Endocrinol. Metab. 45, 920-930, 1977.

25. Ö. Wrange and J.-Å. Gustafsson: Separation of the hormone- and DNA-binding sites of the hepatic glucocorticoid receptor by means of proteolysis. J. Biol. Chem. 253, 856-865, 1978.

26. Ö. Wrange, B. Nordenskjöld and J.-Å. Gustafsson: Cytosol estradiol receptor in human mammary carcinoma: An assay based on isoelectric focusing in polyacrylamide gel. Anal. Biochem. 85, 461-475, 1978.

27. J.-Å. Gustafsson, P. Eneroth, T. Hökfelt and P. Skett: Central control of hepatic steroid metabolism: effect of discrete hypothalamic lesions. Endocrinology 103, 141-151, 1978.

28. Ö. Wrange, J. Carlstedt-Duke and J.-Å. Gustafsson: Purification of the glucocorticoid receptor from rat liver cytosol. J. Biol. Chem. 254, 9284-9290, 1979.

29. A. Berg, M. Ingelman-Sundberg and J.-Å. Gustafsson: Purification and characterization of cytochrome P-450meg. J. Biol. Chem. 254, 5264-5271, 1979.

30. J. Carlstedt-Duke, Ö. Wrange, E. Dahlberg, J.-Å. Gustafsson and B. Högberg: Transformation of the glucocorticoid receptor in rat liver cytosol by lysosomal enzymes. J. Biol. Chem. 254, 1537-1539, 1979.


32. B. Forsgren, P. Björk, K. Carlström, J.-Å. Gustafsson, Å. Pousette and B. Högberg: Purification and distribution of a major protein in rat prostate that binds estramustine, a nitrogen mustard derivative of estradiol-17. Proc. Natl. Acad. Sci. USA 76, 3149-3153, 1979.

33. J.-Å. Gustafsson, Å. Pousette and Ö. Wrange: Predictive tests in treatment of breast and prostatic carcinoma based on steroid receptor assays. Trends Pharmacol. Sci., pp. 279-281, June, 1980.

34. J.E. Bakke, J.-Å. Gustafsson and B.E. Gustafsson: Metabolism of propachlor by the germfree rat. Science 210, 433-435, 1980.

35. S. Okret, J. Carlstedt-Duke, Ö. Wrange, K. Carlström and J.-Å. Gustafsson: Characterization of an antiserum against the glucocorticoid receptor. Biochem. Biophys. Acta 667, 205-219, 1981.

52


36. A. Mode, G. Norstedt, B. Simic, P. Eneroth and J.-Å. Gustafsson: Continuous infusion of growth hormone feminizes hepatic steroid metabolism in the rat. Endocrinology 108, 2103-2108, 1981.

37. F. Payvar, Ö. Wrange, J. Carlstedt-Duke, S. Okret, J.-Å. Gustafsson and K.R. Yamamoto: Purified glucocorticoid receptors bind selectively in vitro to a cloned DNA fragment whose transcription is regulated by glucocorticoids in vivo. Proc. Natl. Acad. Sci. USA 78, 6628-6632, 1981.

38. J. Carlstedt-Duke, S. Okret, Ö. Wrange and J.-Å. Gustafsson: Immunochemical analysis of the glucocorticoid receptor: identification of a third domain separate from the steroid-binding and DNA-binding domains. Proc. Natl. Acad. Sci. USA 79, 4260-4264, 1982.

39. A. Mode, J.-Å. Gustafsson, J.-O. Jansson, S. Edén and O. Isaksson: Association between plasma level of growth hormone and sex differentiation of hepatic steroid metabolism in the rat. Endocrinology 111, 1692-1697, 1982.

40. G. Norstedt, A. Mode, T. Hökfelt, P. Eneroth, R. Elde, L. Ferland, F. Labrie and J.-Å. Gustafsson: Possible role of somatostatin in the regulation of the sexually differentiated steroid metabolism and prolactin receptor in rat liver. Endocrinology 112, 1076-1090, 1983.

41. A. Mode, G. Norstedt, P. Eneroth and J.-Å. Gustafsson: Purification of liver feminizing factor from rat pituitaries and demonstration of its identity with growth hormone. Endocrinology 113, 1250-1260, 1983.

42. F. Payvar D. DeFranco, G.L. Firestone, B. Edgar, Ö. Wrange, S Okret, J.-Å. Gustafsson and K.R. Yamamoto: Sequence-specific binding of glucocorticoid receptor to MTV DNA at sites within and upstream of the transcribed region. Cell 35, 381-392, 1983.

43. J.-Å. Gustafsson, A. Mode and G. Norstedt: Central control of prolactin and estrogen receptors in rat liver - expression of a novel endocrine system, the hypothalamo-pituitary-liver axis. Ann. Rev. Pharmacol. Toxicol. 23, 259-278, 1983.

44. J.-Å. Gustafsson, A. Mode, G. Norstedt and P. Skett: Sex steroid induced changes in hepatic enzymes. Ann. Rev. Physiol. 45, 51-60, 1983.

45. L. Haglund, C. Köhler, T. Haaparanta, M. Goldstein and J.-Å. Gustafsson: Presence of NADPH-cytochrome P-450 reductase in central catecholaminergic neurones. Nature 307, 259-262, 1984.

46. S. Okret, A.-C. Wikström, Ö. Wrange, B. Andersson and J.-Å. Gustafsson:Monoclonal antibodies against the rat liver glucocorticoid receptor. Proc. Natl. Acad. Sci. USA 81, 1609-1613, 1984.

47. Ö. Wrange, S. Okret, M. Radojcic, J. Carlstedt-Duke and J.-Å. Gustafsson: Characterization of the purified activated glucocorticoid receptor from rat liver cytosol. J. Biol. Chem. 259, 4534-4541, 1984.

53


48. R. Miesfeld, S. Okret, A.-C. Wikström, Ö. Wrange, J.-Å. Gustafsson and K. Yamamoto: Characterization of a steroid receptor gene and mRNA in wild-type and mutant cells. Nature 312, 779-781, 1984.

49. J. Bakke, C. Struble, J.-Å. Gustafsson and B. Gustafsson: Catabolism of premercapturic acid pathway metabolites of naphthlene to naphthols and methylthio-containing metabolites in rats. Proc. Natl. Acad. Sci. USA 82, 668-671, 1985.

50. J. Lund, I. Brandt, L. Poellinger, Å. Bergman, E. Klasson-Wehler and J.-Å. Gustafsson: Target cells for the polychlorinated biphenyl metabolite 4,4'-bis(methylsulfonyl)-2,2',5,5'-tetrachlorobiphenyl. Characterization of high affinity binding in rat and mouse lung cytosol. Mol. Pharmacol. 27, 314-323, 1985.

51. M. Gillner, J. Bergman, C. Cambillau, B. Fernström and J.-Å. Gustafsson: Interactions of indoles with specific binding sites for 2,3,7,8-tetrachlorodibenzo-p-dioxin in rat liver. Mol. Pharmacol. 28, 357-363, 1985.

52. J.-O. Jansson, S. Ekberg, O. Isaksson, A. Mode and J.-Å. Gustafsson: Imprinting of growth hormone secretion, body growth, and hepatic steroid metabolism by neonatal testosterone. Endocrinology 117, 1881-1889, 1985.

53. K. Fuxe, A.-C. Wikström, S. Okret, L.F. Agnati, A. Härfstrand, Z.-Y. Yu, L. Granholm, M. Zoli, W. Vale and J.-Å. Gustafsson: Mapping of glucocorticoid receptor immunoreactive neurons in the rat tel- and diencephalon using a monoclonal antibody against rat liver glucocorticoid receptor. Endocrinology 117, 1803-1812, 1985.

54. S. Okret, L. Poellinger, Y. Dong and J.-Å. Gustafsson: Down-regulation of glucocorticoid receptor mRNA by glucocorticoid hormones and recognition by the receptor of a specific binding sequence within a receptor cDNA clone. Proc. Natl. Acad.Sci. USA 83, 5899-5903, 1986.

55. R. Miesfield, S. Rusconi, P.J. Godowski, B.A. Maler, S. Okret, A.-C. Wikström, J.-Å. Gustafsson and K.R. Yamamoto: Genetic complementation of a glucocorticoid receptor deficiency by expression of cloned receptor cDNA. Cell 46, 389-399, 1986.

56. Ö. Wrange, J. Carlstedt-Duke and J.-Å. Gustafsson: Stoichiometric analysis of the specific interaction of the glucocorticoid receptor with DNA. J. Biol. Chem. 261, 11770-11778, 1986.

57. J. Carlstedt-Duke, P.-E. Strömstedt, Ö. Wrange, T. Bergman, J.-Å. Gustafsson: Domain structure of the glucocorticoid receptor protein. Proc. Natl. Acad. Sci. USA 84, 4437-4440, 1987.

58. M. Denis, A.-C. Wikström and J.-Å. Gustafsson: The molybdate-stabilized non-activated glucocorticoid receptor contains a dimer of Mr 90,000 non-hormone-binding protein. J. Biol. Chem. 262, 11803-11806, 1987.

59. J.-Å. Gustafsson, J. Carlstedt-Duke, L. Poellinger, S. Okret, A.-C. Wikström, M. Brönnegård, M. Gillner, Y. Dong, K. Fuxe, A. Cintra, A. Härfstrand and L. Agnati: Biochemistry, molecular biology, and physiology of the glucocorticoid receptor. Endocrine Reviews 8, 185-234, 1987.

54


60. A. Hecht, A. Berkenstam, P.-E. Strömstedt, J.-Å. Gustafsson and A.E. Sippel: A progesterone responsive element maps to the far upstream steroid dependent DNase hypersensitive site of chicken lysozyme chromatin. EMBO J. 7, 2063-2073, 1988.

61. P.G. Zaphiropoulos, A. Mode, A. Ström, C. Möller, C. Fernandez and J.-Å. Gustafsson: cDNA cloning, sequence, and regulation of a major female-specific and growth hormone-inducible rat liver cytochrome P-450 active in 15-hydroxylation of steroid sulfates. Proc. Natl. Acad. Sci. USA 85, 4214-4217, 1988.

62. D.D. Sakai, S. Helms, J. Carlstedt-Duke, J.-Å. Gustafsson, F.M. Rottman and K.R. Yamamoto: Hormone-mediated repression: a negative glucocorticoid response element from the bovine prolactin gene. Genes & Development 2, 1144-1154, 1988.

63. J. Carlstedt-Duke, P.-E. Strömstedt, B. Persson, E. Cederlund, J.-Å. Gustafsson and H. Jörnvall: Identification of hormone-interacting amino acid residues within the steroid-binding domain of the glucocorticoid receptor in relation to other steroid hormone receptors. J. Biol. Chem. 263, 6843-6846, 1988.

64. M. Denis, L. Poellinger, A.-C. Wikström and J.-Å. Gustafsson: Requirement of hormone for thermal conversion of the glucocorticoid receptor to a DNA-binding state. Nature 33, 686-688, 1988.

65. S.Y. Tsai, J. Carlstedt-Duke, N.L. Weigel, K. Dahlman, J.-Å. Gustafsson, M.-J. Tsai and B.W. O'Malley: Molecular interactions of steroid hormone receptor with its enhancer element: evidence for receptor dimer formation. Cell 55, 361-369, 1988.

66. P.S. Guzelian, D. Li, E.G. Schuetz, P. Thomas, W. Levin, A. Mode and J.-Å. Gustafsson: Sex change in cytochrome P-450 phenotype by growth hormone treatment of adult rat hepatocytes maintained in a culture system on matrigel. Proc. Natl. Acad. Sci. USA 85, 9783-9787, 1988.

67. M. Aronsson, K. Fuxe, Y. Dong, L.F. Agnati, S. Okret and J.-Å. Gustafsson: Localization of glucocorticoid receptor mRNA in the male rat brain by in situ hybridization. Proc. Natl. Acad. Sci. USA 85, 9331-9335, 1988.

68. P.G. Zaphiropoulos, A. Mode, G. Norstedt and J.-Å. Gustafsson: Regulation of sexual differentiation in drug and steroid metabolism. Trends Pharmacol. Sci., 10, 149-153, 1989.

69. K. Dahlman, P.-E. Strömstedt, C. Rae, H. Jörnvall, J.-I. Flock, J. Carlstedt-Duke and J.-Å. Gustafsson: High level expression in Escherichia coli of the DNA-binding domain of the glucocorticoid receptor in a functional form utilizing domain-specific cleavage of a fusion protein. J. Biol. Chem. 264, 804-809, 1989

70. M. Warner, M. Strömstedt, L. Möller and J.-Å. Gustafsson: Distribution and regulation of 5-androstane-3,17-diol hydroxylase in the rat central nervous system. Endocrinology 124, 1246-2699, 1989.

71. Y. Dong, M. Aronsson, J.-Å. Gustafsson and S. Okret: The mechanism of cAMP-induced glucocorticoid receptor expression. Correlation to cellular glucocorticoid response. J. Biol. Chem. 23, 13679-13686, 1989.

55


72. A. Mode, E. Wiersma-Larsson and J.-Å. Gustafsson: Transcriptional and posttranscriptional regulation of sexually differentiated rat liver cytochrome P-450 by growth hormone. Mol. Endocrinol. 3, 1142-1147, 1989.

73. P.G. Zaphiropoulos, A. Ström, J.A. Robertson and J.-Å. Gustafsson: Structural and regulatory analysis of the male-specific rat liver cytochrome P-450g: Repression by continuous growth hormone administration. Mol. Endocrinol. 4, 53-58, 1990.

74. L. Nordlund-Möller, O. Andersson, R. Ahlgren, J. Schilling, M. Gillner, J.-Å. Gustafsson and J. Lund: Cloning, structure, and expression of a rat binding protein for polychlorinated biphenyls. J. Biol. Chem., 265, 12690-12693, 1990.

75. E. Imai, P.-E. Strömstedt, P. G. Quinn, J. Carlstedt-Duke, J.-Å. Gustafsson and D. K. Granner: Characterization of a complex glucocorticoid response unit in the phosphoenolpyruvate carboxykinase gene. Mol.Cell. Biol., 10, 4712-4719, 1990.

76. T. Härd, E. Kellenbach, R. Boelens, B. A. Maler, K. Dahlman, L. P. Freedman, J. Carlstedt-Duke, K. R. Yamamoto, J.-Å. Gustafsson, and R. Kaptein: Solution structure of the glucocorticoid receptor DNA-binding domain. Science, 249, 157-160, 1990.

77. P.-E. Strömstedt, L. Poellinger, J.-Å. Gustafsson, and J. Carlstedt-Duke: The Glucocorticoid Receptor Binds to a Sequence Overlapping the TATA Box of the Human Osteocalcin Promoter: a Potential Mechanism for Negative Regulation. Mol. Cell. Biol, 11, 3379-3383, 1991.

78. A.P.H. Wright, I.J. McEwan, K. Dahlman-Wright, and J.-Å. Gustafsson: High level expression of the major transactivation domain of the human glucocorticoid receptor in yeast cells inhibits endogenous gene expression and cell growth. Mol. Endocrinology.,5, 1366-1372, 1991.

79. M. Göttlicher, E. Widmark, Q. Li, and J.-Å. Gustafsson: Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc.Natl.Acad.Sci. USA, 89, 4653-4657, 1992.

80. M. Rudling, G. Norstedt, H. Olivecrona, E. Reihnér, J.-Å. Gustafsson and B. Angelin: Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc.Natl.Acad.Sci. USA, 89, 6983-6987, 1992.

81. L. Poellinger, M. Göttlicher and J.-Å. Gustafsson: The dioxin and peroxisome proliferator-activated receptors: nuclear receptors in search of endogenous ligands. Trends Pharmacol. Sci., 13, 241-245, 1992.

82. I.J. McEwan, A.P.H. Wright, K. Dahlman-Wright, J. Carlstedt-Duke, and J.-Å. Gustafsson: Direct interaction of the 1 transactivation domain of the human glucocorticoid receptor with the basal transcriptional machinery. Mol. Cell. Biol., 13, 399-407, 1993.

83. K. L. Gearing, M. Göttlicher, M. Teboul, E. Widmark, and J.-Å. Gustafsson: Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc. Natl. Acad. Sci. USA, 90, 1440-1444, 1993.

56


84. M. Gillner, J. Bergman, C. Cambillau, M. Alexandersson, B. Fernström, and J.-Å. Gustafsson: Interactions of indolo[3,2-b]carbazoles and related polycyclic aromatic hydrocarbons with specific binding sites for 2,3,7,8-tetrachlorodibenzo-p-dioxin in rat liver. Mol. Pharmacol., 44, 336-345, 1993.

85. C.D. Banner, M. Göttlicher, E. Widmark, J. Sjövall, J.J. Rafter, and J.-Å. Gustafsson: A systematic analytical chemistry/cell assay approach to isolate activators of orphan nuclear receptor from biological extracts: characterization of peroxisome proliferator-activated receptor activators in plasma. J. Lipid Res., 34, 1583-1591, 1993.

86. T. Härd and J.-Å. Gustafsson: Structure and function of the DNA-binding domain of the glucocorticoid receptor and other members of the nuclear receptor supergene family. Accounts of Chem. Res., 26, 644-650, 1993.

87. M. Warner and J.-Å. Gustafsson: Effect of ethanol on cytochrome P450 in the rat brain. Proc. Natl. Acad. Sci. USA., 91, 1019-1023, 1994.

88. K. Dahlman-Wright, T. Almlöf, I.J. McEwan, J.-Å. Gustafsson and A.P.H. Wright: Delineation of a small region within the major transactivation domain of the human glucocorticoid receptor that mediates transactivation of gene expression. Proc. Natl. Acad. Sci. USA. 91, 1619-1623, 1994.

89. J. Zilliacus, J. Carlstedt-Duke, J.-Å. Gustafsson and A.P.H. Wright: Evolution of distinct DNA-binding specificities within the nuclear receptor family of transcription factors. Proc.Natl. Acad. Sci. USA., 91, 4175-4179, 1994.

90. H. E. Witkowska, C. H. L. Shackleton, K. Dahlman-Wright, J. Y. Kim, and J.-Å. Gustafsson: Mass spectrometric analysis of a native zinc-finger structure: The glucocorticoid receptor DNA binding domain. J. Am. Chem. Society, 117, 3319-3324, 1995.

91. M. Teboul, E. Enmark, Q. Li, A.C. Wikström, M. Pelto-Huikko, and J.-Å. Gustafsson: OR-1, a member of the nuclear receptor superfamily that interacts with the 9-cis-retinoic acid receptor. Proc. Natl. Acad. Sci. USA, 92, 2096-2100, 1995.

92. E. Caldenhoven, J. Lidén, S. Wissink, A. Van de Stolpe, J. Raaijmakers, L. Koenderman, S. Okret, J.-Å. Gustafsson, and P. T. Van der Saag: Negative cross-talk between ReIA and the glucocorticoid receptor: A possible mechanism for the antiinflammatory action of glucocorticoids. Mol. Endocrinol. 9, 401-412, 1995.

93. K. Dahlman-Wright, H. Baumann, I. J. McEwan, T. Almlöf, A.P.H. Wright, J.-Å. Gustafsson, and T. Härd: Structural characterization of a minimal functional transactivation domain from the human glucocorticoid receptor. Proc.Natl.Acad.Sci. USA, 92, 1699-1703, 1995.

94. T. Härd, H.J. Barnes, C. Larsson, J.-Å. Gustafsson and J. Lund: Solution structure of a mammalian PCB-binding protein in complex with a PCB. Nature Struct. Biol.2, 983-989, 1995.

95. M. Warner and J.-Å. Gustafsson: Cytochrome P450 in the brain: Neuroendocrine functions. Frontiers in Neuroendocrinology, 16, 224-236, 1995.

57


96. E. Enmark and J.-Å. Gustafsson: Orphan nuclear receptor - The first eight years. Mol. Endocrinol. 10, 1293-1307, 1996.

97. G.G.J.M. Kuiper, E. Enmark, M. Pelto-Huikko, S. Nilsson, and J.-Å. Gustafsson: Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc.Natl.Acad.Sci. USA 93, 5925-5930, 1996.

98. G. Spyrou, E. Enmark, A. Miranda-Vizuete, and J.-Å. Gustafsson: Cloning and expression of a novel mammalian thioredoxin. J. Biol. Chem., 272, 2936-2941, 1997.

99. T. Almlöf, J.-Å. Gustafsson, and A.P.H. Wright: Role of hydrophobic amino acid clusters in the transactivation activity of the human glucocorticoid receptor. Mol. Cell Biol., 17, 934-945, 1997.

100. M. Byers, G.G.J.M. Kuiper, J.-Å. Gustafsson, and O.-K. Park-Sarge: Estrogen receptor- mRNA expression in rat ovary: Down-regulation by gonadotropins. Mol. Endocrinol. 11, 172-182, 1997.

101. A. Henriksson, T. Almlöf, J. Ford, I.J. McEwan, J.-Å. Gustafsson and A.P.H. Wright: Role of the Ada Adaptor Complex in Gene Activation by the Glucocorticoid Receptor. Mol. Cell Biol. 3065-3073, 1997.

102. K. Pettersson, K. Grandien, G. G. J. M. Kuiper and J.-Å. Gustafsson: Mouse estrogen receptor forms estrogen response element binding heterodimers with estrogen receptor . Mol. Endocrinol. 11, 1486-1496, 1997.

103. K. Paech, P. Webb, G. G.J.M. Kuiper, S. Nilsson, J.-Å. Gustafsson, P. J.Kushner, and T. S. Scanlan: Differential transactivation properties of the estrogen receptor isotypes (, ): Estrogen-like effects with antiestrogens and antiestrogen effects with estrogen. Science, 277, 1508-1510, 1997.

104. A.M. Brzozowski, A.C.W. Pike, Z. Dauter, R.E. Hubbard, T. Bonn, O. Engström, L. Öhman, G.L. Greene, J.-Å. Gustafsson and M. Carlquist: Insights into the molecular basis of agonism and antagonism in the oestrogen receptor as revealed by complexes with 17-oestradiol and raloxifene. Nature, 389, 753-758, 1997.

105. F.F. Wiebel, J.-Å. Gustafsson: Heterodimeric interaction between RXR and orphan nuclear receptor OR1 reveals dimerization-induced activation as a novel mechanism of nuclear receptor activation. Mol. Cell. Biol., 17, 3977-3986, 1997.

106. F. Delaunay, A. Khan, A. Cintra, B. Davani, Z.-C. Ling, A. Andersson, C.-G. Östenson, J.-Å. Gustafsson, S. Efendic, and S. Okret: Pancreatic -cells are important targets for the diabetogenic effects of glucocorticoids. J. Clin. Invest. 100, 2094-2098, 1997.

107. E. Enmark, M. Pelto-Huikko, K. Grandien, S. Lagercrantz, J. Lagercrantz, G. Fried, M. Nordenskjöld and J.-Å. Gustafsson: Human estrogen receptor -gene structure, chromosomal localization and expression pattern. J. Clin. Endocrinol. Metab., 82, 4258-4265, 1997.

58


108. J.-Å. Gustafsson: Estrogen receptor - Getting in on the action? Nature Medicine, 3, 493-494, 1997.

109. E. Treuter, T. Albrektsen, L. Johansson, J. Leers, and J.-Å. Gustafsson: A regulatory role for RIP140 in nuclear receptor activation. Mol. Endocrinol., 12, 864-881, 1998.

110. G.G.J.M. Kuiper, J.G. Lemmen, B. Carlsson, J.C. Corton, S.H. Safe, P. T. van der Saag, B. van der Burg, and J.-Å. Gustafsson: Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor . Endocrinology, 139, 4252-4263, 1998.

111. J. H. Krege, J. B. Hodgin, J. F. Couse, E. Enmark, M. Warner, J. F. Mahler, M. Sar, K. S. Korach, J.-Å. Gustafsson, and O. Smithies: Generation and reproductive phenotypes of mice lacking estrogen receptor . Proc.Natl.Acad.Sci. USA, 95, 15677-15682, 1998.

112. G.G.J.M. Kuiper, P.J. Shughrue, M. Pelto-Huikko, I. Merchenthaler and J.-Å. Gustafsson: The estrogen receptor subtype: A novel mediator of estrogen action in neuroendocrine systems. Frontiers in Neuroendocrinol, 19, 253-286, 1998.

113. J.-Å. Gustafsson: Raloxifene: Magic bullet for heart and bone? Nature Medicine, 4, 152, 1998.

114. S. Nilsson, G. Kuiper and J.-Å. Gustafsson: ER: a novel estrogen receptor offers the potential for new drug development. Trends Endocrin. Met., 9, 387-395, 1998.

115. J.-Å. Gustafsson: Therapeutic potential of selective estrogen receptor modulators. Current Opinion in Chemical Biology, 2, 508-511, 1998.

116. G.G.J.M. Kuiper, M. Carlquist, and J.-Å. Gustafsson: Estrogen is a male and female hormone. Science & Medicine, 5, 36-45, 1998.

117. A.Dumont, S.P. Hehner, M.L. Schimtz, J.-Å. Gustafsson, J. Lidén, S. Okret, P. T. van der Saag, S. Wissink, B. van der Burg, P. Herrlich, G. Haegeman, K. de Bosscher and W. Fiers: Cross-talk between steroids and NF-B: what language? Trends Biochem. Sci., 233-235, 1998.

118. Johansson, J. S. Thomsen, A. E. Damdimopoulos, G. Spyrou, J.-Å. Gustafsson, and E. Treuter: The orphan nuclear receptor SHP inhibits agonist-dependent transcriptional activity of estrogen receptors ER and ER. J. Biol. Chem., 247, 345-353, 1999.

119. E. Treuter, L. Johansson, J.S. Thomsen, A. Wärnmark, J. Leers, M. Pelto-Huikko, M. Sjöberg, A.P.H. Wright, G. Spyrou, and J.-Å. Gustafsson: Competition between thyroid hormone receptor-associated protein (TRAP) 220 and transcriptional intermediary factor (TIF) 2 for binding to nuclear receptors. J. Biol. Chem., 274, 6667-6677, 1999.

120. S. Mäkelä, H. Savolainen, E. Aavik, M. Myllärniemi, L. Strauss, E. Taskinen, J.-Å. Gustafsson, and P. Häyry: Differentiation between vasculoprotective and uterotrophic effects of ligands with different binding affinities to estrogen receptors and . Proc. Natl. Acad. Sci. USA, 96, 7077-7082, 1999.

59


121. J.-M. Vanacker, K. Pettersson, J.-Å. Gustafsson and V. Laudet: Transcriptional targets shared by estrogen receptor-related receptors (ERRs) and estrogen receptor (ER) , but not by ER. EMBO J. 18, 4270-4279, 1999.

122. A.C.W. Pike, A.M. Brzozowski, R.E. Hubbard, T. Bonn, A.-G. Thorsell, O. Engström, J. Ljunggren, J.-Å. Gustafsson and M. Carlquist: Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist. EMBO J., 18, 4608-4618, 1999.

123. S. Ogawa, J. Chan, A.E. Chester, J.-Å. Gustafsson, K.S. Korach, and D.W. Pfaff: Survival of reproductive behaviors in estrogen receptor gene-deficient (ERKO) male and female mice. Proc.Natl.Acad.Sci.USA, 96, 12887-12892, 1999.

124. S.H Windahl, O. Vidal, G. Andersson, J.-Å. Gustafsson, and C. Ohlsson: Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ER -/- mice. J. Clin. Invest., 104, 895-901, 1999.

125. J.-Å. Gustafsson: Seeking ligands for lonely orphan receptors. Science, 284, 1285-1286, 1999.

126. L.D. Croce, S. Okret, S. Kersten, J.-Å. Gustafsson, M. Parker, W. Wahli and M. Beato: Steroid and nuclear receptors. EMBO J., 18, 6201-6210, 1999.

127. S. Saji, E. V. Jensen, S. Nilsson, T. Rylander, M. Warner, and J.-Å. Gustafsson: Estrogen receptors and in the rodent mammary gland. Proc.Natl.Acad.Sci. USA, 97, 337-342, 2000.

128. F. Caira, P. Antonson, M. Pelto-Huikko, E. Treuter, and J.-Å. Gustafsson: Cloning and characterization of RAP250, a novel nuclear receptor coactivator. J. Biol. Chem. 275, 5308-5317, 2000.

129. C. Patrone, G. Pollio, E. Vegeto, E. Enmark, I. de Curtis, J.-Å. Gustafsson and A. Maggi: Estradiol induces differential neuronal phenotypes by activating estrogen receptor or . Endocrinol., 141, 1839-1845, 2000.

130. Z. Weihua, S. Saji, S. Mäkinen, G. Cheng, E. V. Jensen, M. Warner and J.-Å. Gustafsson: Estrogen receptor (ER) ,a modulator of ER in the uterus. Proc.Natl.Acad.Sci. USA, 97, 5936-5941, 2000.

131. K. Pettersson, F. Dalaunay, and J.-Å. Gustafsson: Estrogen receptor acts as a dominant regulator of estrogen signaling. Oncogene, 19, 4970-4978, 2000.

132. C. M. Sadek, S. Jalaguier, E P. Feeney, M. Aitola, A. E. Damdimopoulos, M. Pelto-Huikko, J.-Å. Gustafsson. Isolation and characterization of AINT: a novel ARNT interacting protein expressed during murine embryonic development. Mechanisms of Development 97, 13-26, 2000.

133. A. Ström, N. Arai, J. Leers, and J.-Å. Gustafsson. The Hairy and Enhancer of Split homologue-1 (HES-1) mediates the proliferative effect of 17-estradiol on breast cancer cell lines. Oncogene, 19, 5951-5953, 2000.

60


134. H. Zhang, J. S. Thomsen, L. Johansson, J.-Å. Gustafsson, and E. Treuter. DAX-1 functions as an LXXLL-containing corepressor for activated estrogen receptors. J. Biol. Chem., 275, 39855-39859, 2000.

135. S. Ogawa, A.E. Chester, S. Curtis Hewitt, V. R. Walker, J.-Å. Gustafsson, O. Smithies, K.S. Korach, and D. W. Pfaff. Abolition of male sexual behaviors in mice lacking estrogen receptors and (ERKO). Proc.Natl.Acad.Sci. USA, 97, 14737-14741, 2000.

136. C. Palmieri, S. Saji, J.-Å. Gustafsson, R C. Coombes: False negatives in oestrogen-receptor assay. The Lancet, 356, 944, 2000.

137. E. Enmark and J.-Å. Gustafsson: Nematode genome sequence dramatically extends the nuclear receptor superfamily. Trends Pharmacol. Sci., 21, 85-87, 2000.

138. L. Wang, S. Andersson, M. Warner, and J.-Å. Gustafsson: Morphological abnormalities in the brains of estrogen receptor knockout mice. Proc.Natl.Acad.Sci. USA, 98, 2792-2796, 2001.

139. S. Alberti, G. Schuster, P. Parini, D. Feltkamp, U. Diczfalusy, M. Rudling, B. Angelin, I. Björkhem, S. Pettersson, and J.-Å. Gustafsson: Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXR-deficient mice. J. Clin. Invest., 107, 565-573, 2001.

140. A. C. W. Pike, A. M. Brzozowski, J. Walton, R. E. Hubbard, A.-G. Thorsell, Y.-L. Li, J.-Å. Gustafsson, and M. Carlquist: Structural insights into the mode of action of a pure antiestrogen. Structure, 9, 145-153, 2001.

141. Z. Weihua, S. Mäkelä, L. C. Andersson, S. Salmi, S. Saji, J. I. Webster, E. V. Jensen, S. Nilsson, M. Warner, and J.-Å. Gustafsson: A role for estrogen receptor in the regulation of growth of the ventral prostate. Proc.Natl.Acad.Sci. USA, 98, 6330-6335, 2001.

142. K. Rose, A. Allan, S. Gauldie, G. Stapleton, L. Dobbie, K. Dott, C. Martin, L. Wang, E. Hedlund, J. R. Seckl, J.-Å. Gustafsson, and R. Lathe: Neurosteroid hydroxylase CYP7B vivid reporter activity in dentate gyrus of gene-targeted mice and abolition of a widespread pathway of steroid and oxysterol hydroxylation. J. Biol. Chem., 276, 23937-23944, 2001.

143. L. G. Horvath, S. M.. Henshall, C.-S. Lee, D. R. Head, D. I. Quinn, S. Makela, W. Delprado, D. Golovsky, P. C. Brenner, G. O’Neill, R. Kooner, P. D. Stricker, J. J. Grygiel, J.-Å. Gustafsson, and R. L. Sutherland: Frequent loss of estrogen receptor- expression in prostate cancer. Cancer Res., 61, 5331-5335, 2001.

144. S.H. Windahl, K. Hollberg, O. Vidal, J.-Å. Gustafsson, C. Ohlsson, and G. Andersson: Female estrogen receptor -/- mice are partially protected against age-related trabecular bone loss. J. Bone and Mineral Res., 16, 2001.

145. K. Pettersson and J.-Å. Gustafsson: Role of estrogen receptor beta in estrogen action. Annu. Rev. Physiol., 63, 165-92, 2001.

146. S. Nilsson, S. Mäkelä, E. Treuter, M. Tujague, J. Thomsen, G. Andersson, E. Enmark, K. Pettersson, M. Warner, and J.-Å. Gustafsson: Mechanism of estrogen action. Physiol. Rev. 81, 1535-1565, 2001.

61


147. E. Enmark and J.-Å. Gustafsson: Comparing nuclear receptors in worms, flies and humans. Trends Pharmacol. Sci., 22, 611-615, 2001.

148. Y. Zhu, Z. Bian, P. Lu, R. H. Karas, L. Bao, D. Cox, J. Hodgin, P. W. Shaul, P. Thorén, O. Smithies, J.-Å. Gustafsson, M. E. Mendelsohn: Abnormal vascular function and hypertension in mice deficient in estrogen receptor . Science, 295, 505-508, 2002.

149. C. Palmieri, G. J. Cheng, S. Saji, M. Zelada-Hedman, A. Wärri, Z. Weihua, S. Van Noorden, T. Wahlstrom, R. C. Coombes, M. Warner, and J.-Å. Gustafsson: Estrogen receptor beta in breast cancer. Endocrine-Related Cancer, 9, 1-13, 2002.

150. E.F. Rissman, A. L. Heck, J. E. Leonard, M. A. Shupnik, and J.-Å. Gustafsson: Disruption of estrogen receptor gene impairs spatial learning in female mice. Proc.Natl.Acad.Sci. USA, 99, 3996-4001, 2002.

151. K. A. Risan Tobin, S. M. Ulven, G. U. Schuster, H. Hermansen Steineger, S. M. Andresen, J.-Å. Gustafsson, and H. I. Nebb: Liver X receptors as insuling-mediating factors in fatty acid and cholesterol biosynthesis. J. Biol. Chem., 277, 10691-10697, 2002.

152. A. Båvner, L. Johansson, G. Toresson, J.-Å. Gustafsson, E. Treuter: A transcriptional inhibitor targeted by the atypical orphan nuclear receptor SHP. EMBO reports, 5, 478-484, 2002.

153. L. Wang, S. Andersson, M. Warner and J.-Å. Gustafsson: Estrogen actions in the brain. Science STKE, 138, 2002. http://stke.sciencemag.org/cgi/content/full/sigtrans;2002/138/pe29

154. T. M. Stulnig, U. Opperman, K. R. Steffensen, G. U. Schuster and J.-Å. Gustafsson: Liver X receptor downregulates 11-hydroxysteroid dehydrogenase type 1 expression and activity. Diabetes, 51, 2426-2433, 2002.

155. G. U. Schuster, P. Parini, L. Wang, S. Alberti, K. R. Steffensen, G. K. Hansson, B. Angelin, J.-Å. Gustafsson: Accumulation of foam cells in liver X receptor-deficient mice. Circulation, 106, 1147-1153, 2002.

156. L. Wang, G. U. Schuster, K. Hultenby, Q. Zhang, S. Andersson, and J.-Å. Gustafsson: Liver X receptors in the central nervous system: From lipid homeostasis to neuronal degeneration. Proc.Natl.Acad.Sci. USA, 99, 13878-13883, 2002.

157. Z. Weihua, R. Lathe, M. Warner, and J.-Å. Gustafsson: An endocrine pathway in the prostate, ER, AR, 5-androstane-3, 17-diol, and CYP7B1, regulates prostate growth. Proc.Natl.Acad.Sci. USA, 99, 13589-13594, 2002.

158. T. M. Stulnig, K.R. Steffensen, H. Gao, M. Reimers, K. Dahlman-Wright, G. U. Schuster, and J.-Å. Gustafsson: Novel roles of liver X receptors exposed by gene expression profiling in liver and adipose tissue. Mol. Pharmacol., 62, 1299-1305, 2002.

159. C. Förster, S. Mäkelä, A. Wärri, S. Kietz, D. Becker, K. Hultenby, M. Warner, and J.-Å. Gustafsson: Involvement of estrogen receptor in terminal differentiation of mammary gland epithelium. Proc. Natl. Acad. Sci. USA, 99, 15578-15583, 2002.

62

http://stke.sciencemag.org/cgi/content/full/sigtrans;2002/138/pe29


160. S. H. Windahl, G. Andersson, and J.-Å. Gustafsson: Elucidation of estrogen receptor function in bone with the use of mouse models. Trends Endocrin. Met., 13, 195-200, 2002.

161. S. Nilsson and J.-Å. Gustafsson: Biological role of estrogen and estrogen receptors. Critical Rev. Biochem. Mol. Biol., 37, 1-28, 2002.

162. L. Wang, S. Andersson, M. Warner, and J.-Å. Gustafsson: Estrogen receptor (ER) knockout mice reveal a role for ER in migration of corticol neurons in the developing brain. Proc. Natl. Acad. Sci. USA, 100, 703-708, 2003.

163. M. K. Lindberg, S. Movérare, S. Skrtic, H. Gao, K. Dahlman-Wright, J.-Å. Gustafsson, and C. Ohlsson: Estrogen receptor (ER)-reduces ER-regulated gene transcription, supporting a “ying yang” relationship between ER and ER in mice. Mol. Endocrinol. 17, 203-208, 2003.

164. G.J. Shim, L. Wang, S. Andersson, N. Nagy, L. Levente Kis, Q. Zhang, S. Mäkelä, M. Warner and J.-Å. Gustafsson: Disruption of the estrogen receptor beta gene in mice causes myeloproliferative disease resembling chronic myeloid leukemia with lymphoid blast crisis. Proc. Natl. Acad. Sci. USA., 100, 6694-6699, 2003.

165. M. Färnegårdh, T. Bonn, S. Sun, J. Ljunggren, H. Ahola, A. Wilhelmsson, J.-Å. Gustafsson, and M. Carlquist: The three-dimensional structure of the liver X receptor reveals a flexible ligand-binding pocket that can accommodate fundamentally different ligands. J. Biol. Chem., 278, 38821-38828, 2003.

166. C. Patrone, T. N. Cassel, K. Pettersson, Y.-S. Piao, G. Cheng, P. Ciana, A. Maggi, M. Warner, J.-Å. Gustafsson, and M. Nord: Regulation of postnatal lung development and homeostasis by estrogen receptor . Mol. Cell. Biol., 23, 8542-8552, 2003.

167. K. T. Dalen, S. M. Ulven, K. Bamberg, J.-Å. Gustafsson, and H. I. Nebb: Expression of the insulin-responsive glucose transporter GLUT4 in adipocytes is dependent on liver X receptor . J. Biol. Chem., 278, 48283-48291, 2003.

168. C. Zhao, E. W.-F. Lam, A. Sunters, E. Enmark, M. Tamburo De Bella, R.C. Coombes, J.-Å. Gustafsson, and K. Dahlman-Wright: Expression of estrogen receptor isoforms in normal breast epithelial cells and breast cancer: regulation by methylation. Oncogene, 22, 7600-7606, 2003.

169. J.-Å. Gustafsson: What pharmacologists can learn from recent advances in estrogen signaling. Trends Pharmacol. Sci., 2003.

170. M. Nilsson, S. Naessén, I. Dahlman, A. Lindén Hirschberg, J.-Å. Gustafsson and K. Dahlman-Wright: Association of estrogen receptor gene polymorphisms with bulimic disease in women. Mol. Psychiatry, 9, 28-34, 2004.

171. A. Ström, J. Hartman, J.S. Foster, S. Kietz, J. Wimalasena, and J.-Å. Gustafsson: Estrogen receptor inhibits 17-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc. Natl. Acad. Sci. USA, 101, 1566-1571, 2004.

63


172. G.-J. Shim, L. Levente Kis, M. Warner, and J.-Å. Gustafsson. Autoimmune glomerulonephritis with spontaneous formation of splenic germinal centers in mice lacking the estrogen receptor alpha gene. Proc. Natl. Acad. Sci. USA, 101, 1720-1724, 2004.

173. G. Cheng, Z. Weihua, M. Warner, and J.-Å. Gustafsson: Estrogen receptors ER and ER in proliferation in the rodent mammary gland. Proc. Natl. Acad. Sci. USA, 101, 3739-3746, 2004.

174. N. Heldring, M. Nilsson, B. Buehrer, E. Treuter, and J.-Å. Gustafsson: Identification of tamoxifen-induced coregulator interaction surfaces within the ligand-binding domain of estrogen receptors. Mol. Cell Biol., 24, 3445-3459, 2004.

175. C. Palmieri, E. W.-F. Lam, J. Mansi, C. MacDonald, S. Shousha, P. Madden, Y. Omoto, A. Sunters, M. Warner, J.-Å. Gustafsson and R.C. Coombes: The expression of ERcx in human breast cancer and the relationship to endocrine therapy and survival. Clin. Cancer Res., 10, 2421-2428, 2004.

176. O. Imamov, A. Morani, G.-J. Shim, Y. Omoto, C. Thulin-Andersson, M. Warner, and J.-Å. Gustafsson: Estrogen receptor regulates epithelial cellular differentiation in the mouse ventral prostate. Proc. Natl. Acad. Sci. USA., 101, 9375-9380, 2004.

177. G.-J. Shim, M. Warner, H.-J. Kim, S. Andersson, L. Liu, J. Ekman, O. Imamov, M. E. Jones, E. R. Simpson, and J.-Å. Gustafsson: Aromatase-deficient mice spontaneously develop a lymphoproliferative autoimmune disease resembling Sjögren’s syndrome. Proc. Natl. Acad. Sci. USA., 101, 12628-12633, 2004.

178. M. Esslimani-Sahla, J. Simony-Lafontaine, A. Kramar, R. Lavaill, C. Mollevi, M. Warner, J.-Å. Gustafsson, and H. Rochefort: Estrogen receptor (ER) level but not its ERcx variant helps to predict tamoxifen resistance in breast cancer. Clin. Cancer Res., 10, 5769-5776, 2004.

179. C. Förster, S. Kietz, K. Hultenby, M. Warner, and J.-Å. Gustafsson: Characterization of the ER -/- mouse heart. Proc. Natl. Acad. Sci. USA., 101, 14234-14239, 2004.

180. J. Hartman, P. Müller, J. S. Foster, J. Wimalasena, J.-Å. Gustafsson, and A. Ström: HES-1 inhibits 17-estradiol and heregulin-1-mediated upregulation of E2F-1. Oncogene, 23, 8826-8833, 2004.

181. O. Imamov, N. A. Lopatkin, J.-Å. Gustafsson: Estrogen receptor beta in prostate cancer. N. Engl. J. Med., 351, 2773-2774, 2004.

182. K. Steffensen and J.-Å. Gustafsson: Putative metabolic effects of the liver X receptor (LXR). Diabetes, 53, S36-S42, 2004.

183. H. Gronemeyer, J.-Å. Gustafsson, and V. Laudet: Principles for modulation of the nuclear receptor superfamily. Nature Reviews Drug Discovery, 3, 950-964, 2004.

184. Y. Omoto, O. Imamov, M. Warner, and J.-Å. Gustafsson: Estrogen receptor and imprinting of the neonatal mouse ventral prostate by estrogen. Proc. Natl. Acad. Sci. USA., 102, 1484-1489, 2005.

64


185. Y. Omoto, R. Lathe, M. Warner, and J.-Å. Gustafsson: Early onset of puberty and ovarian failure in CYP7B1 knockout mice. Proc. Natl. Acad. Sci. USA., 102, 2814-2819, 2005.

186. S. Andersson, N. Gustafsson, M. Warner, and J.-Å. Gustafsson: Inactivation of liver X receptor leads to adult-onset motor neuron degeneration in male mice. Proc. Natl. Acad. Sci. USA., 102, 3857-3862, 2005.

187. A.E. Kudwa, C. Bodo, J.-Å. Gustafsson, and E. F. Rissman: A previously uncharacterized role for estrogen receptor : Defeminization of male brain and behavior. Proc. Natl. Acad. Sci. USA., 102, 4608-4612, 2005.

188. M. Esslimani-Sahla, A. Kramar, J. Simony-Lafontaine, M. Warner, J.-Å. Gustafsson, and H. Rochefort: Increased estrogen receptor cx expression during mammary carcinogenesis. Clin. Cancer Res., 11, 3170-3174, 2005.

189. K. M. Robertson, G. U. Schuster, K. R. Steffensen, O. Hovatta, S. Meaney, K. Hultenby, L. C. Johansson, K. Svechnikov, O. Söder, and J.-Å. Gustafsson: The liver X receptor- is essential for maintaining cholesterol homeostasis in the testis. Endocrinology, 146, 2519-2530, 2005.

190. F. Morello, R. A. de Boer, K. R. Steffensen, M. Gnecchi, J. W. Chisholm, F. Boomsma, L. M. Anderson, R. M. Lawn, J.-Å. Gustafsson, M. Lopez-Ilasaca, R. E. Pratt, and V. J. Dzau: Liver X receptors and regulate renin expression in vivo, J. Clin. Invest. 115, 1913-1922, 2005.

191. A. Båvner, J. Matthews, S. Sanyal, J.-Å. Gustafsson and E. Treuter: EID3 is a novel EID family member and an inhibitor of CBP-dependent co-activation. Nucleic Acids Res., 33, 3561-3569, 2005.

192. K. F. Koehler, L. A. Helguero, L.-A. Haldosén, M. Warner, and J.-Å. Gustafsson: Reflections on the discovery and significance of estrogen receptor . Endocrine Rev., 29, 465-478, 2005.

193. J.-Å. Gustafsson: Steroids and the scientist. Mol. Endocrinol., 19, 1412-1417, 2005.

194. A. Båvner, S. Sanyal, J.-Å. Gustafsson and E. Treuter: Transcriptional corepression by SHP: molecular mechanisms and physiological consequences. Trends Endocrin. Met, 16, 478-488, 2005.

195. R. P. A. Barros, U. F. Machado, M. Warner, and J.-Å. Gustafsson: Muscle GLUT4 regulation by estrogen receptors ER and ER. Proc. Natl. Acad. Sci. USA., 103, 1605-1608, 2006.

196. O. Wada-Hiraike, O. Imamov, H. Hiraike, K. Hultenby, T. Schwend, Y. Omoto, M. Warner, and J.-Å. Gustafsson: Role of estrogen receptor in colonic epithelium. Proc. Natl. Acad. Sci. USA., 103, 2959-2964, 2006.

197. J. Matthews, B. Wihlén, M. Tujague, J. Wan, A. Ström, and J.-Å. Gustafsson: Estrogen receptor (ER) modulates ER-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen responsive promoters. Mol. Endo., 20, 534-543, 2006.

65


198. C. Thellenberg-Karlsson, S. Lindström, B. Malmer, F. Wiklund, K. Augustsson-Bälter, H.-O. Adami, P. Stattin, M. Nilsson, K. Dahlman-Wright, J.-Å. Gustafsson, and H. Grönberg: Estrogen receptor polymorphism is associated with prostate cancer risk. Clin. Cancer Res., 12, 1936-1941, 2006.

199. A. Morani, R. P. A. Barros, O. Imamov, K. Hultenby, A. Arner, M. Warner, and J.-Å. Gustafsson: Lung dysfunction causes systemic hypoxia in estrogen receptor knockout (ER-/-) mice. Proc. Natl. Acad. Sci. USA., 103, 7165-7169, 2006.

200. H. Gao, G. Bryzgalova, E. Hedman, A. Khan, S. Efendic, J.-Å. Gustafsson, and K. Dahlman-Wright: Long-term administration of estradiol decreases expression of hepatic lipogenic genes and improves insulin sensitivity in ob/ob mice: A possible mechanism is through direct regulation of signal transducer and activator of transcription 3. Mol. Endocrinol., 6, 1287-1299, 2006.

201. K. M. Robertson, M. Norgård, S. H. Windahl, K. Hultenby, C. Ohlsson, G. Andersson, and J.-Å. Gustafsson: Cholesterol-sensing receptors, liver X receptor and , have novel and distinct roles in osteoclast differentiation and activation. J. Bone Min. Res., 21, 1276-1287, 2006.

202. O. Wada-Hiraike, H. Hiraike, H. Okinaga, O. Imamov, R. P. A. Barros, A. Morani, Y. Omoto, M. Warner and J.-Å. Gustafsson: Role of estrogen receptor in uterine stroma and epithelium: Insights from estrogen receptor mice. Proc. Natl. Acad. Sci. USA., 103, 18350-18355, 2006.

203. J. Hartman, K. Lindberg, A. Morani, J. Inzunza, A. Ström, and J.-Å. Gustafsson: Estrogen receptor inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res., 23, 11207-11213, 2006.

204. X. Fan, M. Warner, and J.-Å. Gustafsson: Estrogen receptor expression in the embryonic brain regulates development of calretinin-immunoreactive GABAergic interneurons. Proc. Natl. Acad. Sci. USA., 103, 19338-19343, 2006.

205. R. P. A. Barros, U. F. Machado, and J.-Å. Gustafsson: Estrogen receptors: new players in diabetes mellitus. Trends Mol. Med., 12, 425-431, 2006.

206. U. Ohnemus, M. Uenalan, J. Inzunza, J.-Å. Gustafsson and R. Paus: The hair follicle as an estrogen target and source. Endocrine Rev., 6, 677-706, 2006.

207. J. Inzunza, A. Morani, G. Cheng, M. Warner, J. Hreinsson, J.-Å. Gustafsson, and O. Hovatta: Ovarian wedge resection restores fertility in estrogen receptor knockout (ER-/-) mice. Proc. Natl. Acad. Sci. USA, 104, 600-605, 2007.

208. C. Zhao, J. Matthews, M. Tujague, J. Wan, A. Ström, G. Toresson, E. W-F. Lam, G. Cheng, J.-Å. Gustafsson and K. Dahlman-Wright: Estrogen receptor 2 negatively regulates the transactivation of estrogen receptor in human breast cancer cells. Cancer Res., 67, 3955-3962, 2007.

209. O. Imamov, K. Yakimchuk, A. Morani, T. Schwend, O. Wada-Hiraike, S. Razumov, M. Warner and J.-Å. Gustafsson: Estrogen receptor deficient female mice develop a

66


bladder phenotype resembling human interstitial cystitis. Proc. Natl. Acad. Sci. USA, 104, 9806-9809, 2007.

210. X. Fan, H.-J. Kim, M. Warner, and J.-Å.Gustafsson: Estrogen receptor is essential for sprouting of nociceptive primary afferents and for morphogenesis and maintenance of the dorsal horn interneurons. Proc. Natl. Acad. Sci. USA, 104, 13696-13701, 2007.

211. C.-Y. Lin, A. Ström, S. L. Kong, S. Kietz, J. S. Thomsen, J. B. S. Tee, V. B. Vega, L. D. Miller, J. Smeds, J. Bergh, J.-Å. Gustafsson, and E. T. Liu: Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer. Breast Cancer Res., 9:R25, 1-11, 2007.

212. S. Sanyal, A. Båvner, A. Haroniti, L.-M. Nilsson, T. Lundåsen, S. Rehnmark, M. Robin Witt, C.Einarsson, I. Talianidis, J.-Å. Gustafsson, E. Treuter: Involvement of corepressor complex subunit GPS2 in transcriptional pathways governing human bile acid biosynthesis. Proc. Natl. Acad. Sci. USA, 104, 15665-15670, 2007.

213. E.. Treuter, and J.-Å. Gustafsson: Wrestling rules in transrepression: As easy as SUMO-1, -2, -3? Mol. Cell, 25, 178-180, 2007.

214. N. Heldring, A. Pike, S. Andersson, J. Matthews, G. Cheng, J. Hartman, M. Tujague, A. Ström, E. Treuter, M. Warner, and J.-Å. Gustafsson: Estrogen receptors: How do they signal and what are their targets? Physiol. Rev., 87, 905-931, 2007.

215. H. Gao, S. Fält, A. Sandelin, J.-Å. Gustafsson, and K. Dahlman-Wright: Genome-wide identification of estrogen receptor -binding sites in mouse liver. Mol. Endocrinol., 22, 10-22, 2008.

216. H.-J. Kim, X. Fan, C. Gabbi, K. Yakimchuk, P. Parini, M. Warner, and J.-Å. Gustafsson: Liver X receptor (LXR): A link between -sitosterol and amyotrophic lateral sclerosis-Parkinson’s dementia. Proc. Natl. Acad. Sci. USA, 105, 2094-2099, 2008.

217. C. Williams, K. Edvardsson, S.A. Lewandowski, A. Ström and J.-Å. Gustafsson: A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Oncogene, 27, 1019-1032, 2008.

218. Y. Liu, H. Gao, T. T. Marstrand, A. Ström, E. Valen, A. Sandelin, J.-Å. Gustafsson, and K. Dahlman-Wright: The genome landscape of ERα- and ERβ-binding DNA regions. Proc. Natl. Acad. Sci. USA, 105, 2604-2609, 2008.

219. I. Meltser, Y. Tahera, E. Simpson, M. Hultcrantz, K. Charitidi, J.-Å. Gustafsson, and B. Canlon: Estrogen receptor β protects against acoustic trauma in mice. J. Clin. Investigation, 118, 1563-1570, 2008.

220. A. Foryst-Ludwig, M. Clemenz, S. Hohmann, M. Hartge, C. Sprang, N. Frost, M. Krikov, S. Bhanot, R. Barros, A. Morani, J.-Å. Gustafsson, T. Unger and U. Kintscher: Metabolic actions of estrogen receptor beta (ERβ) are mediated by a negative cross-talk with PPARγ. PLoS Genetics, 4, 1-16, 2008.

67


221. X. Fan, H.-J. Kim, D. Bouton, M. Warner, and J.-Å. Gustafsson: Expression of liver X receptor β is essential for formation of superficial cortical layers and migration of later-born neurons. Proc. Natl. Acad. Sci. USA, 105, 13445-13450, 2008.

222. C. Gabbi, H.-J. Kim, K. Hultenby, D. Bouton, G. Toresson, M. Warner, and J.-Å. Gustafsson: Pancreatic exocrine insufficiency in LXRβ-/- mice is associated with a reduction in aquaporin-1 expression. Proc. Natl. Acad. Sci. USA, 105, 15052-15057, 2008.

223. H.-J. Kim, L. C. Andersson, D. Bouton, M. Warner, and J.-Å. Gustafsson: Stromal growth and epithelial cell proliferation in ventral prostates of liver X receptor knockout mice. Proc. Natl. Acad. Sci. USA, 106, 558-563, 2009.

224. N. Sugiyama, S. Andersson, R. Lathe, X. Fan, P. Alonso-Magdalena, T. Schwend, I. Nalvarte, M. Warner and J.-Å. Gustafsson: Spatiotemporal dynamics of the expression of estrogen receptors in the postnatal mouse brain. Mol. Psychiatry, 14, 223-232, 2009.

225. C. Gabbi, M. Warner and J.-Å. Gustafsson: Minireview: Liver X receptor : Emerging roles in physiology and diseases. Mol. Endocrinol., 23, 129-136, 2009.

226. K. Ogasawara, H. Nogami, M. C. Tsuda, J.-Å. Gustafsson, K. S. Korach, S. Ogawa, T. Harigaya, and S. Hisano: Hormonal regulation of prolactin cell development in the fetal pituitary gland of the mouse. Endocrinology, 150, 1061-1068, 2009.

227. P. Alonso-Magdalena, C. Brössner, A. Reiner, G. Cheng, N. Sugiyama, M. Warner, and J.-Å. Gustafsson: A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia. Proc. Natl. Acad. Sci. USA, Early Edition, 2009.

Top 10 publications

1. Ö. Wrange and J.-Å. Gustafsson: Separation of the hormone- and DNA-binding sites of the hepatic glucocorticoid receptor by means of proteolysis. J. Biol. Chem. 253, 856-865, 1978.

FIRST DEMONSTRATION OF DOMAIN STRUCTURE OF A NUCLEAR RECEPTOR


FIRST PURIFICATION OF A NUCLEAR RECEPTOR TO HOMOGENEITY

3. F. Payvar, Ö. Wrange, J. Carlstedt-Duke, S. Okret, J.-Å. Gustafsson and K.R. Yamamoto: Purified glucocorticoid receptors bind selectively in vitro to a cloned DNA fragment whose transcription is regulated by glucocorticoids in vivo. Proc. Natl. Acad. Sci. USA 78, 6628-6632, 1981.

FIRST DEMONSTRATION OF SPECIFIC BINDING OF A NUCLEAR RECEPTOR TO DNA

68


4. R. Miesfeld, S. Okret, A.-C. Wikström, Ö. Wrange, J.-Å. Gustafsson and K. Yamamoto: Characterization of a steroid receptor gene and mRNA in wild-type and mutant cells. Nature 312, 779-781, 1984.

FIRST CLONING OF A NUCLEAR RECEPTOR cDNA

5. T. Härd, E. Kellenbach, R. Boelens, B. A. Maler, K. Dahlman, L. P. Freedman, J. Carlstedt-Duke, K. R. Yamamoto, J.-Å. Gustafsson, and R. Kaptein: Solution structure of the glucocorticoid receptor DNA-binding domain. Science, 249, 157-160, 1990.

FIRST 3-D STRUCTURE OF A NUCLEAR RECEPTOR DOMAIN (THE DBD)

6. M. Göttlicher, E. Widmark, Q. Li, and J.-Å. Gustafsson: Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. Proc.Natl.Acad.Sci. USA, 89, 4653-4657, 1992.

FIRST DESCRIBED ACTIVATORS OF AN ORPHAN NUCLEAR RECEPTOR (FATTY ACIDS FOR PPARα)

7. M. Teboul, E. Enmark, Q. Li, A.C. Wikström, M. Pelto-Huikko, and J.-Å. Gustafsson: OR-1, a member of the nuclear receptor superfamily that interacts with the 9-cis-retinoic acid receptor. Proc. Natl. Acad. Sci. USA, 92, 2096-2100, 1995.

DISCOVERY OF LXRβ

8. G.G.J.M. Kuiper, E. Enmark, M. Pelto-Huikko, S. Nilsson, and J.-Å. Gustafsson: Cloning of a novel estrogen receptor expressed in rat prostate and ovary. Proc.Natl.Acad.Sci. USA, 93, 5925-5930, 1996.

DISCOVERY OF THE 2ND ESTROGEN RECEPTOR, ERβ, CAUSING A PARADIGM SHIFT IN OUR UNDERSTANDING OF ESTROGEN SIGNALING

9. A.M. Brzozowski, A.C.W. Pike, Z. Dauter, R.E. Hubbard, T. Bonn, O. Engström, L. Öhman, G.L. Greene, J.-Å. Gustafsson and M. Carlquist: Insights into the molecular basis of agonism and antagonism in the oestrogen receptor as revealed by complexes with 17β-oestradiol and raloxifene. Nature, 389, 753-758, 1997.

DISCOVERY OF THE MOLECULAR MECHANISM OF ANTAGONISM (HELIX 12 PERTURBATION) WITHIN NUCLEAR RECEPTORS

10. Z. Weihua, S. Mäkelä, L. C. Andersson, S. Salmi, S. Saji, J. I. Webster, E. V. Jensen, S. Nilsson, M. Warner, and J.-Å. Gustafsson: A role for estrogen receptor in the regulation of growth of the ventral prostate. Proc.Natl.Acad.Sci. USA, 98, 6330-6335, 2001.

DISCOVERY OF THE REGULATORY ROLE OF ERβ IN THE GROWTH OF THE PROSTATE

69

Documents

CURRICULUM VITAE - MD Anderson Cancer Center GI_Cancer... · Web viewV Int. Symposium on Microsomes and Drug Oxidations, Tokyo, Japan: "Central control of sexual differentiation of